BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We describe a 38-year-old woman with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) who developed two symmetric paramalleolar ulcers with similar diameters, depths and borders, that were successfully treated with photodynamic therapy with 5-aminolevulinic acid (ALA-PDT).

[MeSH-minor] Adult. Aminolevulinic Acid / therapeutic use. Antiphospholipid Syndrome / complications. Antiphospholipid Syndrome / drug therapy. Antiphospholipid Syndrome / pathology. Female. Humans. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / drug therapy. Lupus Erythematosus, Systemic / pathology. Photosensitizing Agents / therapeutic use

MedlinePlus Health Information. consumer health - Autoimmune Diseases.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17973045.001).

[ISSN] 1474-905X

[Journal-full-title] Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology

[ISO-abbreviation] Photochem. Photobiol. Sci.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Currently, Arsenic Trioxide (ATO) is considered the treatment of choice for patients with relapsed acute promyelocytic leukemia (APL).

Recently, a durable remission with minimal toxicity by single agent ATO or ATO + ATRA in newly diagnosed APL was reported by different groups.

These regimens have minimal toxicity and can be administered on an outpatient basis after remission induction, thus they could become a real, less toxic and more economic option to ATRA + anthracyclines in particular in low risk APL, or in patients that cannot undergo chemotherapy because of age or comorbid conditions and in patients that refuse chemotherapy.

Significantly, these therapies are a successful attempt to cure a tumoral disease without chemotherapy.

The results of clinical trials of ATO administration as single agent in multiple myeloma (MM) and myelodisplastic syndromes (MDS) were encouraging and showed clinical effects but they were not close to APL success.

On the contrary, results of clinical trials to treat non-APL acute myeloid leukemia (AML) were disappointing.

We suggest that a combination therapy with drugs targeting specific pro-survival molecules or capable to enhance pro-apoptotic pathways may lead to an improvement of ATO efficacy against hematological malignancies, in particular AML.

Our pre-clinical studies showed that ATO is capable to induce cell death in acute leukemia cells but the apoptotic function is limited since it can induce also a mechanism of cell defense by activating pro-survival molecules such as MEK-ERK, Bcl-xL, Bcl-2.

By combining ATO with specific MEK inhibitors, we demonstrated that the block of MEK-ERK phosphorylation, the induction of Bad de-phosphorylation, and activation of p53AIP1 apoptotic pathway interrupt the pro-survival mechanisms of ATO and kill the leukemic cells by apoptotic synergism.

Our results provide an experimental basis for combined or sequential treatment with MEK inhibitors and ATO in AML.

[MeSH-major] Arsenicals / therapeutic use. Clinical Trials as Topic / trends. Hematologic Neoplasms / drug therapy. Multiple Myeloma / drug therapy. Oxides / therapeutic use

MedlinePlus Health Information. consumer health - Clinical Trials.

MedlinePlus Health Information. consumer health - Multiple Myeloma.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17168655.001).

[ISSN] 1873-4316

[Journal-full-title] Current pharmaceutical biotechnology

[ISO-abbreviation] Curr Pharm Biotechnol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide

[Number-of-references] 62

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

This study was purposed to explore the inhibitory effect of Curcumin on growth of retinoic acid-resistant acute promyelocytic leukemia (APL) cells and its mechanism.

The NB4-R1, an APL cell line resistant to retinoic acid, was used as a model.

The growth level of NB4-R1 was detected by MTT assay, the morphologic features of cells were observed by light microscopy, the mitochondrial transmembrane potential was determined by flow cytometry, the expressions of apoptosis-related proteins procaspase 3, caspase 3, PARP and BCL-XL were measured by Western blot.

The morphologic observation showed existence of apoptotic bodies in NB4-R1 cells treated with 20 micromol/L of Curcumin.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

Hazardous Substances Data Bank. CURCUMIN .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20416164.001).

[ISSN] 1009-2137

[Journal-full-title] Zhongguo shi yan xue ye xue za zhi

[ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi

[Language] CHI

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / bcl-X Protein; 5688UTC01R / Tretinoin; EC 2.4.2.30 / PARP1 protein, human; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; IT942ZTH98 / Curcumin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice.

Antiphospholipid (aPL) antibodies bind to beta2glycoprotein I (beta2GPI) and cause endothelial cell (EC) activation and thrombosis in mice. beta2GPI binds to EC through its Vth domain and induces their activation.

TIFI is a 20 amino acid synthetic peptide that shares similarity with the Vth domain of beta2GPI.

Our objectives were to examine the ability of TIFI to affect aPL-mediated thrombosis in mice and the interactions of TIFI, beta2GPI with phospholipid surfaces and target cells.

CD1 mice were injected with IgG from a patient with antiphospholipid syndrome (IgG-APS) or with control IgG-NHS and with either TIFI or with control peptide (VITT).

Inhibition and competition studies were done using aPL antibodies, cardiolipin (CL) liposomes in the presence of varying amounts of TIFI and beta2GPI.

TIFI reverted the beta2GPI-dependent binding of aPL antibodies to CL liposomes in a dose-dependent fashion.

This effect was abrogated by addition of beta2GPI, suggesting that TIFI displaces the binding of beta2GPI to phospholipids.

The data indicate that TIFI abrogates thrombogenic properties of aPL in mice by competing with beta2GPI and preventing its binding to target cells.

[MeSH-major] Antiphospholipid Syndrome / immunology. Fibrinolytic Agents / therapeutic use. Peptides / therapeutic use. Thrombosis / prevention & control. beta 2-Glycoprotein I / chemistry

[MeSH-minor] Amino Acid Sequence. Animals. Antibodies, Antiphospholipid / blood. Antibodies, Antiphospholipid / immunology. Antibodies, Antiphospholipid / toxicity. Binding, Competitive. Cardiolipins / immunology. Cells, Cultured. Endothelium, Vascular / drug effects. Endothelium, Vascular / physiopathology. Enzyme-Linked Immunosorbent Assay. Humans. Immunoglobulin G / toxicity. Liposomes. Macrophages / drug effects. Macrophages / immunology. Male. Mice. Molecular Mimicry. Molecular Sequence Data. Neutralization Tests. Protein Binding / drug effects. Protein Structure, Tertiary

Genetic Alliance. consumer health - Thrombosis.

MedlinePlus Health Information. consumer health - Blood Clots.

COS Scholar Universe. author profiles.

Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16830882.001).

[ISSN] 0961-2033

[Journal-full-title] Lupus

[ISO-abbreviation] Lupus

[Language] eng

[Grant] United States / NCRR NIH HHS / RR / G12-RR03034; United States / NIGMS NIH HHS / GM / S02GM08248

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Cardiolipins; 0 / Fibrinolytic Agents; 0 / Immunoglobulin G; 0 / Liposomes; 0 / Peptides; 0 / TIFI peptide; 0 / beta 2-Glycoprotein I

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prevalence and clinical correlation of anti-phospholipid-binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages.

CONTEXT: Anti-phospholipid antibodies (aPL) are a heterogeneous group of autoantibodies, the presence of which is associated with thrombotic events and miscarriage.

OBJECTIVE: To establish whether antibodies directed against phospholipid-binding plasma proteins such as beta(2)-glycoprotein I (beta(2)GPI), prothrombin (PT), and annexin V (Anx V) constitute a risk factor for thromboembolism in patients with systemic lupus erythematosus (SLE) and for miscarriage in women with recurrent pregnancy loss (RPL), independently of the presence of the classic anticardiolipin (aCL) antibodies, and whether their determination together with that of aCL would help to increase the diagnostic sensitivity of aPL tests.

DESIGN: The prevalence of various antibodies directed toward phospholipids (CL and other anionic phospholipids [APL]) and phospholipid-binding proteins (beta(2)GPI, PT, and Anx V) was determined by immunoenzymatic methods in 311 serum samples.

PATIENTS: Twenty-five patients with aCL-positive primary anti-phospholipid syndrome (pAPS); 89 patients with SLE, 23 of whom had thrombotic complications (SLE/APS) and 66 of whom had no thrombosis; and 77 women with unexplained recurrent pregnancy loss comprised our study group.

RESULTS: Immunoglobulin (Ig) G and/or IgM aAPL, anti-beta(2)GPI, anti-PT, and IgG anti-Anx V antibodies were detected in 25 (100%), 20 (80%), 15 (60%), and 6 (24%), respectively, of the 25 aCL-positive pAPS patients; IgG and/or IgM aCL, aAPL, anti-beta(2)GPI, anti-PT, and IgG anti-Anx V antibodies were detected in 33 (37%), 42 (47%), 31 (35%), 40 (45%), and 12 (13%) of the 89 SLE patients, respectively.

Of the 56 SLE patients who proved to be aCL negative, anti-beta(2)GPI was present in 3 patients (5%), anti-PT in 13 (23%) patients, and anti-Anx V in 5 (9%) patients.

In the subset of 23 SLE/APS patients, IgG anti-PT prevalence was higher than that of the other autoantibodies (87% vs 70% aCL, 66% aAPL, 57% anti-beta(2)GPI, and 4% anti-Anx V), and in 26% of cases, IgG anti-PT was the only antibody present.

Anti-PT had a slightly lower specificity than aCL (46% vs 49%); however, the occurrence of both antibodies brought the specificity to 92.4%.

The highest risk for thrombosis in SLE patients was associated with the presence of IgG anti-PT antibody (odds ratio [OR] 15.3, P < .001, vs 6.5 aCL, 3.5 aAPL, 3.4 anti-beta(2)GPI, 0.2 anti-Anx V).

Fifty-one of the 77 women with recurrent pregnancy loss were negative for all antibodies investigated; the prevalence of IgG and/or IgM aCL, aAPL, anti-beta(2)GPI, anti-PT, and IgG anti-Anx V antibodies was 6% (5), 12% (9), 6% (5), 16% (12), and 17% (13), respectively.

Of the 67 aCL-negative women, none had anti-beta(2)GPI antibodies, 7 (11%) were anti-PT positive, and 13 (19%) were anti-Anx V positive.

In the subgroup of 26 recurrent pregnancy loss patients who had at least one antibody, anti-Anx V was present in 50% of cases (in 42% as the sole antibody) and was the only antibody significantly associated with miscarriage (P = .02).

CONCLUSIONS: The results of this study indicate that it is useful to measure anti-PT antibodies in addition to the more widely used aCL and anti-beta(2)GPI antibodies in the prognostic evaluation of SLE patients for the risk of thrombosis, and the results also confirm that anti-Anx V antibodies may play an important role in recurrent pregnancy loss.

[MeSH-major] Abortion, Spontaneous / blood. Antibodies, Anticardiolipin / blood. Antibodies, Antiphospholipid / blood. Antiphospholipid Syndrome / blood. Lupus Erythematosus, Systemic / blood

[MeSH-minor] Adult. Annexin A5 / blood. Annexin A5 / immunology. Autoantibodies / blood. Cardiolipins / immunology. Enzyme-Linked Immunosorbent Assay / methods. Female. Glycoproteins / blood. Glycoproteins / immunology. Humans. Male. Middle Aged. Phospholipids / immunology. Pregnancy. Prevalence. Prothrombin / immunology. Thromboembolism / etiology. beta 2-Glycoprotein I

Genetic Alliance. consumer health - Lupus.

Genetic Alliance. consumer health - Systemic lupus erythematosus.

MedlinePlus Health Information. consumer health - Lupus.

MedlinePlus Health Information. consumer health - Miscarriage.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15628909.001).

[ISSN] 1543-2165

[Journal-full-title] Archives of pathology & laboratory medicine

[ISO-abbreviation] Arch. Pathol. Lab. Med.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Annexin A5; 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid; 0 / Autoantibodies; 0 / Cardiolipins; 0 / Glycoproteins; 0 / Phospholipids; 0 / beta 2-Glycoprotein I; 9001-26-7 / Prothrombin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical relevance of the recent update of the classification criteria for definite antiphospholipid syndrome: an obstetric medicine clinic series of 107 patients.

[MeSH-major] Antiphospholipid Syndrome / classification. Antiphospholipid Syndrome / diagnosis

[MeSH-minor] Antibodies, Antiphospholipid / blood. Female. Humans. Lupus Coagulation Inhibitor / blood. Partial Thromboplastin Time. Phospholipids / chemistry. Pregnancy. Pregnancy Complications / classification. Pregnancy Complications / diagnosis. Pregnancy Complications / immunology. Prognosis. Retrospective Studies

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentOn] J Thromb Haemost. 2006 Feb;4(2):295-306 [16420554.001]

(PMID = 16869832.001).

[ISSN] 1538-7933

[Journal-full-title] Journal of thrombosis and haemostasis : JTH

[ISO-abbreviation] J. Thromb. Haemost.

[Language] eng

[Publication-type] Comment; Letter

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Lupus Coagulation Inhibitor; 0 / Phospholipids

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] TCR ligand avidity determines the mode of B-Raf/Raf-1/ERK activation leading to the activation of human CD4+ T cell clone.

The interactions between peptide/MHC complexes and their cognate TCR are essential for various T cell responses.

However, the relationship between the avidity of TCR ligand and the subsequent intracellular signaling through the TCR is still unclear.

To investigate the effects of TCR ligand avidity on TCR-mediated signaling, we established L cells expressing HLA-DR4 molecules covalently linked with agonistic peptide (high-affinity ligand) or altered peptide ligand (APL; low-affinity ligand) at various densities as APC for a cognate human CD4(+) T cell clone.

Using this system, we demonstrated that the T cell clone stimulated with APL/HLA-DR4 complexes presented at an excessive density provoked the up-regulation of CD69, IL-2 production and proliferation, but no detectable phosphorylation of ZAP-70/LAT/SLP-76.

The strength and duration of B-Raf/ERK activations closely correlated with the density of the TCR ligand.

A knockdown approach confirmed that B-Raf activation was indispensable for the APL-induced T cell responses.

These observations suggest that the differences in TCR-peptide/MHC interactions reflect the strength and duration of B-Raf/Raf-1/ERK activation in the human CD4(+) T cells.

[MeSH-minor] Amino Acid Sequence. Animals. Aotidae. Cell Transformation, Viral. Cells, Cultured. Clone Cells. Enzyme Activation / immunology. HLA-DR4 Antigen / physiology. Herpesvirus 2, Saimiriine. Humans. Jurkat Cells. L Cells (Cell Line). Ligands. Mice. Mice, Inbred C57BL. Molecular Sequence Data. NIH 3T3 Cells. PC12 Cells. Rats

COS Scholar Universe. author profiles.

Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .

National BioResource Project. culture/stock collections - NBRP resources .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16791876.001).

[ISSN] 0014-2980

[Journal-full-title] European journal of immunology

[ISO-abbreviation] Eur. J. Immunol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / HLA-DR4 Antigen; 0 / Ligands; 0 / Receptors, Antigen, T-Cell; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We have shown earlier that IFNgamma and As2O3 act synergistically in acute promyelocytic leukemia cells to upregulate IRF-1 expression and to induce apoptosis.

Here, we show that in the human fibrosarcoma cell line 2fTGH, As2O3 prolongs IFNgamma-induced STAT1 phosphorylation resulting in persistent binding of STAT1 to GAS motif leading to an increase in IRF-1 expression which correlated with both higher anti-proliferative effect and increased apoptosis.

MedlinePlus Health Information. consumer health - Arsenic.

Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16914093.001).

[ISSN] 1165-158X

[Journal-full-title] Cellular and molecular biology (Noisy-le-Grand, France)

[ISO-abbreviation] Cell. Mol. Biol. (Noisy-le-grand)

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] France

[Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / GAS1 protein, human; 0 / GPI-Linked Proteins; 0 / Growth Inhibitors; 0 / Interferon Regulatory Factor-1; 0 / Membrane Proteins; 0 / STAT1 Transcription Factor; 82115-62-6 / Interferon-gamma; N712M78A8G / Arsenic

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Kikuchi's lymphadenopathy: a relatively rare but important cause of lymphadenopathy in Greece, potentially associated with the antiphospholipid syndrome.

Kikuchi-Fujimoto disease is a form of reactive lymphadenopathy, which was firstly described in Japan, but is uncommon in the Western world.

We retrospectively reviewed the medical records of nine cases of adult or adolescent Kikuchi's disease diagnosed in a single Haematology Unit in Athens, Greece between 1990 and 2006.

The median leukocyte count was 4.7 x 10(9)/l (2.2-4.9) with a normal differential in 7/9 patients.

One patient had clinical and laboratory evidence of primary antiphospholipid syndrome (APLS).

In conclusion, Kikuchi's disease represents a rare but important diagnostic possibility for patients presenting with lymphadenopathy in Greece and other western countries.

[MeSH-major] Antiphospholipid Syndrome / diagnosis. Antiphospholipid Syndrome / physiopathology. Histiocytic Necrotizing Lymphadenitis / diagnosis. Histiocytic Necrotizing Lymphadenitis / physiopathology

[MeSH-minor] Adolescent. Adult. Antibodies, Antiphospholipid / analysis. Antibodies, Antiphospholipid / blood. Autoimmune Diseases / diagnosis. Autoimmune Diseases / epidemiology. Autoimmune Diseases / physiopathology. Comorbidity. Diagnosis, Differential. Diagnostic Errors / prevention & control. Female. Greece. Humans. Leukocyte Count. Lymph Nodes / pathology. Male. Prevalence. Spleen / pathology. Spleen / physiopathology. Splenomegaly / diagnosis. Splenomegaly / epidemiology. Splenomegaly / physiopathology. Young Adult

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Diagn Cytopathol. 2001 Oct;25(4):220-4 [11599104.001]

[Cites] Am J Surg Pathol. 1995 Jul;19(7):798-809 [7793478.001]

[Cites] Clin Rheumatol. 1991 Mar;10(1):90-3 [2065516.001]

[Cites] Ann Hematol. 2002 Dec;81(12):732-5 [12483371.001]

[Cites] J Microbiol Immunol Infect. 2005 Feb;38(1):35-40 [15692625.001]

[Cites] N Engl J Med. 2002 Mar 7;346(10):752-63 [11882732.001]

[Cites] In Vivo. 2002 Sep-Oct;16(5):311-6 [12494869.001]

[Cites] Lupus. 1994 Oct;3(5):409-11 [7841995.001]

[Cites] Pathol Int. 2003 Apr;53(4):221-6 [12675765.001]

[Cites] Semin Diagn Pathol. 1988 Nov;5(4):329-45 [3217625.001]

[Cites] Am J Clin Pathol. 2004 Jul;122(1):141-52 [15272543.001]

[Cites] Arch Pathol Lab Med. 1985 Feb;109(2):107-8 [3883942.001]

[Cites] Lupus. 2005;14(12):967-9 [16425578.001]

[Cites] Medicine (Baltimore). 2000 Sep;79(5):338-47 [11039082.001]

[Cites] Rheumatol Int. 2005 May;25(4):303-6 [15645234.001]

[Cites] Clin Rheumatol. 2005 Feb;24(1):60-3 [15517448.001]

[Cites] Am J Med. 1996 Oct;101(4):401-5 [8873511.001]

[Cites] Lupus. 2001;10(2):126-8 [11237125.001]

[Cites] Semin Oncol. 1993 Dec;20(6):570-82 [8296196.001]

[Cites] In Vivo. 2003 Jan-Feb;17(1):51-3 [12655790.001]

(PMID = 19693507.001).

[ISSN] 1437-160X

[Journal-full-title] Rheumatology international

[ISO-abbreviation] Rheumatol. Int.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Thromboembolic and bleeding complications in acute leukemia.

The risk of both thromboembolic and bleeding complications is high in acute leukemia.

This double hazard has a significant negative impact on the morbidity and mortality of patients with this disease.

The clinical manifestations of both complications show special features specific to the form of acute leukemia.

Recognition of these characteristics is important in the diagnosis and management of acute leukemia.

In this article, several additional issues are addressed, including the features of bleeding and thrombosis in acute promyelocytic leukemia, the current understanding of the leukostasis syndrome and the iatrogenic complications including catheter-associated thrombosis, and the adverse effects of therapeutic agents used in acute leukemia.

[MeSH-major] Hemorrhage / etiology. Leukemia / complications. Thromboembolism / etiology

[MeSH-minor] Acute Disease. Blood Vessels / pathology. Drug-Related Side Effects and Adverse Reactions. Humans. Thrombophilia. Thrombosis / complications. Thrombosis / epidemiology

MedlinePlus Health Information. consumer health - Bleeding.

MedlinePlus Health Information. consumer health - Leukemia.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21091148.001).

[ISSN] 1747-4094

[Journal-full-title] Expert review of hematology

[ISO-abbreviation] Expert Rev Hematol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We saw a 34-year-old pregnant woman with acute promyelocytic leukemia, who developed acute respiratory failure from all-trans-retinoic acid (ATRA) syndrome.

She was discharged from the intensive care unit after 12 days.

[MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Myeloid, Acute / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Respiration, Artificial. Respiratory Insufficiency / chemically induced. Tretinoin / adverse effects

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Respiratory Failure.

MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19558746.001).

[ISSN] 0020-1324

[Journal-full-title] Respiratory care

[ISO-abbreviation] Respir Care

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Antiphospholipid antibody: laboratory, pathogenesis and clinical manifestations].

Antiphospholipid antibodies (aPL) represent a heterogeneous group of antibodies that recognize various antigenic targets including beta2 glycoprotein I (beta2GPI), prothrombin (PT), activated protein C, tissue plasminogen activator, plasmin and annexin A2.

The most commonly used tests to detect aPL are: lupus anticoagulant (LAC), a functional coagulation assay, anticardiolipin antibody (aCL) and anti-beta2GPI antibody (anti-beta2GPI), which are enzyme-linked immunoassay (ELISA).

Clinically aPL are associated with thrombosis and/or with pregnancy morbidity.

Apparently aPL alone are unable to induce thrombotic manifestations, but they increase the risk of vascular events that can occur in the presence of another thrombophilic condition; on the other hand obstetrical manifestations were shown to be associated not only to thrombosis but mainly to a direct antibody effect on the trophoblast.

[MeSH-major] Antibodies, Anticardiolipin. Antibodies, Antiphospholipid. Antiphospholipid Syndrome. Lupus Coagulation Inhibitor. Pregnancy Complications. Thrombosis / immunology

MedlinePlus Health Information. consumer health - Blood Clots.

MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20390120.001).

[ISSN] 0048-7449

[Journal-full-title] Reumatismo

[ISO-abbreviation] Reumatismo

[Language] ita

[Publication-type] Comparative Study; English Abstract; Journal Article; Review

[Publication-country] Italy

[Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid; 0 / Autoantibodies; 0 / Lupus Coagulation Inhibitor; 0 / beta 2-Glycoprotein I

[Number-of-references] 69

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Laboratory findings, 7 days postoperatively, showed high levels of immunoglobulin G anticardiolipin antibody.

This case does not match the criteria for antiphospholipid syndrome, but some English-language reports have shown rising antiphospholipid antibody levels, particularly anticardiolipin antibodies, in patients with neoplasm.

In those cases, levels have normalized after successful therapy.

Antiphospholipid antibody levels should be examined before surgery to identify risks of hypercoagulability.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20049910.001).

[ISSN] 1098-2752

[Journal-full-title] Microsurgery

[ISO-abbreviation] Microsurgery

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Anticardiolipin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Thrombophilias and peripheral arterial occlusive disease].

Peripheral arterial occlusive disease is a frequent disease due to the classical vascular risk factors such as smoking, diabetes mellitus, dyslipidemia, and hypertension.

Despite these risk factors, many thrombophilias (physiological inhibitors defects, Factor V Leiden and 20210A prothrombin gene variant, antiphospholipid antibodies, mild hyperhomocysteinemia 15-30micromol/l) can be evoked in some clinical forms of peripheral arterial occlusive disease.

Screening for these thrombophilias is justified in patients with venous thromboembolic disease, or signs of antiphospholipid syndrome and possibly in different situations such as premature atheroma of lower limbs, chronic ischaemia, evolutive disease despite adapted treatment and revascularisation failures without evident technical explanation.

Except for the antiphospholipid syndrome, there is currently no consensus for systematic screening of thrombophilia and treatment in patients with peripheral arterial occlusive disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18554834.001).

[ISSN] 0398-0499

[Journal-full-title] Journal des maladies vasculaires

[ISO-abbreviation] J Mal Vasc

[Language] fre

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] France

[Chemical-registry-number] 0 / Antithrombins; 0 / factor V Leiden; 9001-24-5 / Factor V; 9001-26-7 / Prothrombin

[Number-of-references] 62

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Acute myocardial infarction with variable clinical manifestations: probable catastrophic primary antiphospholipid antibody syndrome: a case report].

A 62-year-old diabetic man was admitted to our hospital because of acute myocardial infarction.

Emergent coronary angiography showed multiple thromboembolic occlusions in the distal circumflex and anterior descending arteries.

These clinical manifestations and laboratory findings suggested catastrophic antiphospholipid antibody syndrome.

Acute myocardial infarction is rare as the initial manifestation of catastrophic antiphospholipid antibody syndrome.

[MeSH-major] Antiphospholipid Syndrome / complications. Myocardial Infarction / etiology

[MeSH-minor] Anticoagulants / therapeutic use. Coronary Angiography. Diabetic Retinopathy / complications. Diagnosis, Differential. Humans. Kidney Diseases / complications. Male. Middle Aged. Prognosis

Genetic Alliance. consumer health - Catastrophic Antiphospholipid Syndrome.

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

MedlinePlus Health Information. consumer health - Heart Attack.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16252568.001).

[ISSN] 0914-5087

[Journal-full-title] Journal of cardiology

[ISO-abbreviation] J Cardiol

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Anticoagulants

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Hyperhomocysteine like thrombocytic risk factor in patient with systemic lupus erythematous with antiphospholipid syndrome].

[Transliterated title] Hiperhomocisteinemia como factor de riesgo trombótico en pacientes con lupus eritematoso sistémico y síndrome antifosfolípido.

OBJECTIVES: to detect the prevalence of hyperhcy in SLE patients with and without antiphospholipid syndrom; to compare the Hcy levels between those patients and healthy controls and to determine the correlation between hyperhcy and antiphospholipid antibodies.

PATIENTS AND METHODS: we studied 44 SLE patients: 17 had antiphospholipid syndrom and 27 didn't have it, and we compared them to 24 healthy controls.

Hyperhcy was present in 27 SLE patients (61,4%), 12 of them had antiphospholipid syndrom.

15(75%) of them had hiperhcy.

[MeSH-major] Antiphospholipid Syndrome / physiopathology. Hyperhomocysteinemia / complications. Lupus Erythematosus, Systemic / physiopathology. Thrombosis / etiology

[MeSH-minor] Adult. Aged. Antibodies, Antiphospholipid / blood. Argentina. Female. Homocysteine / blood. Humans. Male. Middle Aged. Risk Factors. Venous Thrombosis / blood

Genetic Alliance. consumer health - Lupus.

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

MedlinePlus Health Information. consumer health - Blood Clots.

MedlinePlus Health Information. consumer health - Lupus.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16281418.001).

[ISSN] 0014-6722

[Journal-full-title] Revista de la Facultad de Ciencias Médicas (Córdoba, Argentina)

[ISO-abbreviation] Rev Fac Cien Med Univ Nac Cordoba

[Language] spa

[Publication-type] English Abstract; Journal Article

[Publication-country] Argentina

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0LVT1QZ0BA / Homocysteine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The analogs were examined for their antiproliferative activity in vitro against human breast cancer cells (MCF-7) and promyelocytic leukemia (HL-60) cells.

The studies of calcemic activity in vivo showed that analogs PRI-2208 and PRI-2209 did not influence the serum calcium level in doses, in which 1alpha,25(OH)2D3 or (24R)-1,24(OH)2D3 significantly increased this level.

Hazardous Substances Data Bank. CHOLECALCIFEROL .

Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.

(PMID = 20227499.001).

[ISSN] 1879-1220

[Journal-full-title] The Journal of steroid biochemistry and molecular biology

[ISO-abbreviation] J. Steroid Biochem. Mol. Biol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 1C6V77QF41 / Cholecalciferol; SY7Q814VUP / Calcium

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We have identified an intergenic transcriptional activity that is located between the human HOXA1 and HOXA2 genes, shows myeloid-specific expression, and is up-regulated during granulocytic differentiation.

The novel gene, termed HOTAIRM1 (HOX antisense intergenic RNA myeloid 1), is transcribed antisense to the HOXA genes and originates from the same CpG island that embeds the start site of HOXA1.

HOTAIRM1 is the most prominent intergenic transcript expressed and up-regulated during induced granulocytic differentiation of NB4 promyelocytic leukemia and normal human hematopoietic cells; its expression is specific to the myeloid lineage.

Its induction during retinoic acid (RA)-driven granulocytic differentiation is through RA receptor and may depend on the expression of myeloid cell development factors targeted by RA signaling.

Knockdown of HOTAIRM1 quantitatively blunted RA-induced expression of HOXA1 and HOXA4 during the myeloid differentiation of NB4 cells, and selectively attenuated induction of transcripts for the myeloid differentiation genes CD11b and CD18, but did not noticeably impact the more distal HOXA genes.

COS Scholar Universe. author profiles.

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

SciCrunch. HGNC: Data: Gene Annotation .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Cancer Res Clin Oncol. 2000 Jan;126(1):33-40 [10641747.001]

[Cites] Leukemia. 2000 Feb;14(2):255-61 [10673742.001]

[Cites] Transfusion. 2000 Dec;40(12):1475-81 [11134567.001]

[Cites] Stem Cells. 2002;20(5):364-79 [12351808.001]

[Cites] Blood. 2003 Feb 15;101(4):1558-65 [12560242.001]

[Cites] J Cell Biochem. 2003 Jul 1;89(4):848-61 [12858349.001]

[Cites] J Biol Chem. 2003 Nov 28;278(48):47792-802 [14512427.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14603-6 [14638945.001]

[Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]

[Cites] J Leukoc Biol. 2004 Feb;75(2):358-72 [14634056.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2446-51 [14983029.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6508-13 [15096607.001]

[Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W130-4 [15215365.001]

[Cites] Proc Natl Acad Sci U S A. 1980 Sep;77(9):5201-5 [6159641.001]

[Cites] J Leukoc Biol. 1985 Aug;38(2):341-50 [3861749.001]

[Cites] Mech Dev. 1992 Sep;38(3):217-27 [1360810.001]

[Cites] Blood. 1993 Dec 15;82(12):3592-9 [8260698.001]

[Cites] J Clin Invest. 1999 May 15;103(10):1399-408 [10330422.001]

[Cites] Methods Enzymol. 1999;303:272-97 [10349650.001]

[Cites] Exp Hematol. 1999 Sep;27(9):1355-67 [10480426.001]

[Cites] Science. 2004 Dec 24;306(5705):2242-6 [15539566.001]

[Cites] J Exp Zool B Mol Dev Evol. 2005 Jan 15;304(1):75-85 [15643628.001]

[Cites] Mol Cell. 2005 Mar 4;17(5):683-94 [15749018.001]

[Cites] FEBS Lett. 2005 Mar 21;579(8):1795-801 [15763554.001]

[Cites] J Biol Chem. 2005 Apr 1;280(13):12359-70 [15681849.001]

[Cites] Trends Immunol. 2005 Jul;26(7):388-95 [15922663.001]

[Cites] PLoS Biol. 2005 Aug;3(8):e254 [16089502.001]

[Cites] Exp Hematol. 2005 Sep;33(9):1055-61 [16140154.001]

[Cites] BMC Genomics. 2005;6:104 [16083503.001]

[Cites] Nature. 2005 Oct 13;437(7061):1032-7 [16136080.001]

[Cites] Cancer Res. 2005 Oct 15;65(20):9245-52 [16230385.001]

[Cites] Blood. 2005 Dec 1;106(12):3988-94 [16091451.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19081-6 [16357205.001]

[Cites] Curr Opin Hematol. 2006 Mar;13(2):67-73 [16456371.001]

[Cites] Nat Rev Mol Cell Biol. 2006 Aug;7(8):612-6 [16723972.001]

[Cites] Science. 2006 Sep 29;313(5795):1918-22 [17008523.001]

[Cites] Leuk Res. 2007 Jan;31(1):49-57 [16764927.001]

[Cites] PLoS Genet. 2006 Oct 13;2(10):e171 [17040132.001]

[Cites] RNA. 2007 Feb;13(2):223-39 [17185360.001]

[Cites] Gene. 2007 Apr 15;391(1-2):223-32 [17303350.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5527-32 [17369352.001]

[Cites] J Clin Invest. 2007 Apr;117(4):865-8 [17404613.001]

[Cites] PLoS One. 2007;2(4):e356 [17406680.001]

[Cites] Biochem Biophys Res Commun. 2007 Jun 8;357(3):724-30 [17445766.001]

[Cites] J Biol Chem. 2007 Jun 8;282(23):16846-59 [17439948.001]

[Cites] Blood. 2007 Jun 15;109(12):5191-8 [17351112.001]

[Cites] Genome Res. 2007 Jun;17(6):886-97 [17119069.001]

[Cites] Oncogene. 2007 Jun 14;26(28):4115-23 [17213805.001]

[Cites] Nature. 2007 Jun 14;447(7146):799-816 [17571346.001]

[Cites] Cell. 2007 Jun 29;129(7):1311-23 [17604720.001]

[Cites] Blood. 2007 Jul 15;110(2):640-50 [17420285.001]

[Cites] Cell. 2007 Jul 13;130(1):77-88 [17632057.001]

[Cites] PLoS One. 2007;2(7):e630 [17637845.001]

[Cites] Clin Cancer Res. 2007 Sep 1;13(17):5048-55 [17785556.001]

[Cites] Oncogene. 2007 Oct 15;26(47):6766-76 [17934484.001]

[Cites] Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H29-40 [17982008.001]

[Cites] PLoS Genet. 2007 Nov;3(11):e212 [18039033.001]

(PMID = 19144990.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] ENG

[Grant] United States / NHGRI NIH HHS / HG / U01 HG003147; United States / NIDDK NIH HHS / DK / R01 DK054369; United States / NIDDK NIH HHS / DK / DK54369; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400; United States / NHGRI NIH HHS / HG / U01-HG003147

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / DNA, Intergenic; 0 / HOXA2 protein, human; 0 / Homeodomain Proteins; 0 / MicroRNAs; 0 / RNA, Messenger; 0 / Regulatory Sequences, Ribonucleic Acid; 0 / Transcription Factors; 0 / homeobox A1 protein; 0 / long non-coding RNA HOTAIRM1, human; 157907-48-7 / HoxA protein; EC 2.7.7.- / RNA Polymerase II

[Other-IDs] NLM/ PMC2656274

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We reported previously that sequestration of MRE11/RAD50/NBS1 complexes represses ALT-mediated telomere length maintenance, and suppresses formation of ALT-associated promyelocytic leukemia (PML) bodies (APBs).

APBs are PML bodies containing telomeric DNA and telomere-binding proteins, and are observed only in a small fraction of cells within asynchronously dividing ALT-positive cell populations.

We combined methionine restriction with RNA interference to test whether the following proteins are required for APB formation: PML body-associated proteins, PML and Sp100; telomere-associated proteins, TRF1, TRF2, TIN2 and RAP1; and DNA repair proteins, MRE11, RAD50, NBS1 and 53BP1.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. (L)-Methionine .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17297460.001).

[ISSN] 0950-9232

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Autoantigens; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / MRE11A protein, human; 0 / NBN protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / RNA, Small Interfering; 0 / Rad50 protein, human; 0 / TINF2 protein, human; 0 / TP53BP1 protein, human; 0 / Telomere-Binding Proteins; 0 / Telomeric Repeat Binding Protein 1; 0 / Telomeric Repeat Binding Protein 2; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 135844-47-2 / Sp100 protein, human; 143220-95-5 / PML protein, human; AE28F7PNPL / Methionine; EC 6.5.1.- / DNA Repair Enzymes

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Impact of carrier stiffness and microtopology on two-dimensional kinetics of P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) interactions.

Interactions of P-selectin with P-selectin glycoprotein ligand-1 (PSGL-1) were used to demonstrate such effects by presenting the molecules on three carrier systems: human red blood cells (RBCs), human promyelocytic leukemia HL-60 cells, and polystyrene beads.

These results demonstrate that the carrier stiffness and microtopology of a receptor influences its rate of encountering and binding a surface ligand but does not subsequently affect the stability of binding.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17267403.001).

[ISSN] 0021-9258

[Journal-full-title] The Journal of biological chemistry

[ISO-abbreviation] J. Biol. Chem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / P-Selectin; 0 / P-selectin ligand protein

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Antiphospholipid antibodies and coagulation defects in women with implantation failure after IVF and recurrent miscarriage.

Testing for antiphospholipid antibodies or thrombophilia is commonly carried out, and interpretation of results in the light of the current evidence is extremely difficult.

This paper reviews the purported pathogenetic mechanisms and clinical associations between both antiphospholipid antibodies and inherited thrombophilias, and reproductive failure.

The current management strategies are also critically evaluated and recommendations are made for optimal, evidence-based clinical practice.

[MeSH-major] Abortion, Habitual / blood. Abortion, Habitual / immunology. Antibodies, Antiphospholipid / blood. Embryo Implantation / immunology. Thrombophilia / blood

Genetic Alliance. consumer health - Recurrent spontaneous abortion.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16820106.001).

[ISSN] 1472-6483

[Journal-full-title] Reproductive biomedicine online

[ISO-abbreviation] Reprod. Biomed. Online

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Anticoagulants; 0 / Immunoglobulins, Intravenous

[Number-of-references] 96

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The antiphospholipid syndrome.

The antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the clinical association of antiphospholipid autoantibodies (aPL) with a syndrome of hypercoagulability that can affect any blood vessel, irrespective of type or size.

We also discuss the impact that APS may have on pre-existing renal disease as well as current recommendations for treatment of APS.

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] N Engl J Med. 2003 Oct 16;349(16):1526-33 [14561795.001]

[Cites] N Engl J Med. 2003 Sep 18;349(12):1133-8 [13679527.001]

[Cites] Arthritis Rheum. 2003 Nov;48(11):3272-9 [14613293.001]

[Cites] Am J Kidney Dis. 2004 Jan;43(1):28-36 [14712424.001]

[Cites] Arthritis Rheum. 2004 Apr;50(4):1226-32 [15077305.001]

[Cites] Arthritis Rheum. 2004 Aug;50(8):2569-79 [15334471.001]

[Cites] Ann Intern Med. 1992 Aug 15;117(4):303-8 [1637025.001]

[Cites] Ann Intern Med. 1992 Dec 15;117(12):997-1002 [1443986.001]

[Cites] Ann Rheum Dis. 1993 Sep;52(9):689-92 [8239766.001]

[Cites] N Engl J Med. 1995 Apr 13;332(15):993-7 [7885428.001]

[Cites] Lupus. 1996 Jun;5 Suppl 1:S16-22 [8803905.001]

[Cites] J Am Soc Nephrol. 1999 Mar;10(3):507-18 [10073601.001]

[Cites] Blood. 2004 Dec 1;104(12):3598-602 [15315975.001]

[Cites] Blood. 2005 Feb 15;105(4):1540-5 [15507529.001]

[Cites] J Thromb Haemost. 2005 May;3(5):848-53 [15869575.001]

[Cites] Ann Rheum Dis. 2005 Aug;64(8):1205-9 [15708888.001]

[Cites] J Thromb Haemost. 2006 Feb;4(2):295-306 [16420554.001]

[Cites] Blood. 2006 Mar 1;107(5):1916-24 [16269621.001]

[Cites] Rheum Dis Clin North Am. 2006 Feb;32(1):129-48, x [16504826.001]

[Cites] Arthritis Rheum. 2001 Jun;44(6):1466-7 [11407709.001]

[Cites] J Am Soc Nephrol. 2002 Jan;13(1):42-52 [11752020.001]

[Cites] N Engl J Med. 2002 Mar 7;346(10):752-63 [11882732.001]

[Cites] Arthritis Rheum. 2002 Apr;46(4):1019-27 [11953980.001]

[Cites] Rheumatology (Oxford). 2002 Aug;41(8):924-9 [12154210.001]

[Cites] Blood. 2003 Mar 1;101(5):1827-32 [12393574.001]

[Cites] Blood. 2003 May 1;101(9):3495-500 [12531807.001]

[Cites] Ann Rheum Dis. 2003 Jun;62(6):530-3 [12759289.001]

[Cites] Am J Kidney Dis. 2003 Jun;41(6):1205-11 [12776272.001]

[Cites] Lupus. 2003;12(7):530-4 [12892393.001]

[Cites] Arthritis Rheum. 2003 Nov;48(11):3004-8 [14613259.001]

(PMID = 17336687.001).

[ISSN] 0270-9295

[Journal-full-title] Seminars in nephrology

[ISO-abbreviation] Semin. Nephrol.

[Language] ENG

[Grant] None / None / / 67101; Canada / Canadian Institutes of Health Research / / 67101

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 32

[Other-IDs] NLM/ CAMS2313; NLM/ PMC3440307

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: To compare live birth rates in women with recurrent pregnancy loss (RPL) and either autoantibodies or a coagulation abnormality, treated with low molecular weight heparin plus aspirin (LMWH/ASA) or ASA alone, and to place our results in context with other randomized clinical trials (RCT) with similar cohorts.

METHODS: The HepASA Trial was an RCT including patients with a history of RPL and at least 1 of the following: antiphospholipid antibody (aPL), an inherited thrombophilia, or antinuclear antibody.

Treatment groups were stratified by aPL status and history of early versus late pregnancy losses.

RESULTS: Over 4 years, 859 women with RPL were screened: 88 (10.2%) fulfilled inclusion criteria, became pregnant and were randomized to receive either LMWH/ASA or ASA alone. aPL were present in 42 (47.7%) patients in each group.

Neither number of prior losses nor aPL status was correlated with pregnancy outcome.

Mean change in BMD did not differ by treatment group at either the lumbar spine (p = 0.57) or femoral neck (p = 0.15).

RCT since 2000 for aPL positive women with RPL and similar inclusion criteria report a mean live birth rate of 75% with either LMWH or ASA.

Regardless of treatment regimen, number of prior losses, or aPL positivity, almost 80% of women in our RPL cohort had a successful pregnancy outcome.

[MeSH-minor] Adult. Antibodies, Antinuclear / immunology. Anticoagulants / administration & dosage. Antiphospholipid Syndrome / complications. Antiphospholipid Syndrome / drug therapy. Antiphospholipid Syndrome / physiopathology. Bone Density / drug effects. Cohort Studies. Female. Humans. Platelet Aggregation Inhibitors / administration & dosage. Pregnancy. Thrombophilia / complications. Thrombophilia / drug therapy. Thrombophilia / physiopathology. Treatment Outcome

Genetic Alliance. consumer health - Pregnancy.

Genetic Alliance. consumer health - Pregnancy Loss.

MedlinePlus Health Information. consumer health - Autoimmune Diseases.

MedlinePlus Health Information. consumer health - Bleeding Disorders.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] J Rheumatol. 2010 Jan;37(1):202; author reply 203 [20040643.001]

[CommentIn] Curr Rheumatol Rep. 2010 Feb;12(1):1-3 [20425526.001]

(PMID = 19208560.001).

[ISSN] 0315-162X

[Journal-full-title] The Journal of rheumatology

[ISO-abbreviation] J. Rheumatol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] Canada

[Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Anticoagulants; 0 / Heparin, Low-Molecular-Weight; 0 / Platelet Aggregation Inhibitors; R16CO5Y76E / Aspirin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Indications for plasma exchange in systemic lupus erythematosus in 2005.

Plasma exchange can remove putative pathogenic autoantibodies and circulating immune complexes from the blood of patients with systemic lupus erythematosus (SLE).

We review herein the principal historical steps of the use of plasma exchange to treat SLE, based upon the main trials and case reports that have highlighted its most pertinent indications.

Acute life-threatening manifestations and severe therapy-resistant manifestations, like refractory SLE renal disease, diffuse alveolar hemorrhage, neuropsychiatric SLE, thrombotic thrombocytopenic purpura, catastrophic antiphospholipid syndrome, hyperviscosity syndrome and cryoglobulinemia, are the indications for which plasma exchange might have a beneficial therapeutic role.

Although few SLE patients undergo plasma exchange each year nowadays (10-20 per year in France), adverse events are very rare and recent advances in plasma exchange technologies, like immunoadsorption, might, in the future, counterbalance their cost and broaden their place in the therapeutic armamentarium for SLE.

[MeSH-major] Lupus Erythematosus, Systemic / therapy. Plasma Exchange / methods. Plasma Exchange / trends

Genetic Alliance. consumer health - Lupus.

Genetic Alliance. consumer health - Systemic lupus erythematosus.

MedlinePlus Health Information. consumer health - Lupus.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16335578.001).

[ISSN] 0961-2033

[Journal-full-title] Lupus

[ISO-abbreviation] Lupus

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Number-of-references] 100

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] What is the role of arsenic in newly diagnosed APL?

Acute promyelocytic leukemia (APL), a highly curable subtype of acute myeloid leukemia (AML) is characterized by the chromosomal translocation t(15;17) and, consequently, the presence of the PML-RARalpha fusion transcript.

Most patients are treated with all-trans retinoic acid (ATRA), which targets the RAR-alpha moiety of the PML/RAR-alpha fusion transcript, and anthracycline-based chemotherapy.

Arsenic trioxide (ATO) targets the PML moiety and has different mechanisms of action at different concentrations, and induces differentiation and apoptosis.

Several clinical trials have tested the combination of ATRA and ATO with outstanding results.

ATRA plus ATO has emerged as a promising strategy, even for those with high-risk disease.

[MeSH-major] Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19041605.001).

[ISSN] 1532-1924

[Journal-full-title] Best practice & research. Clinical haematology

[ISO-abbreviation] Best Pract Res Clin Haematol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Anthracyclines; 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

[Number-of-references] 31

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Leukemia cutis: a presenting sign in acute promyelocytic leukemia.

[MeSH-major] Leukemia, Promyelocytic, Acute / diagnosis. Skin Neoplasms / diagnosis

[MeSH-minor] Diagnosis, Differential. Female. Humans. Leg Dermatoses / diagnosis. Middle Aged

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17875899.001).

[ISSN] 0003-987X

[Journal-full-title] Archives of dermatology

[ISO-abbreviation] Arch Dermatol

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Arsenic trioxide (ATO) is an effective cancer therapeutic drug for acute promyelocytic leukemia and has potential anticancer activity against a wide range of solid tumors.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

SciCrunch. DrugBank: Data: Chemical .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Med Res Rev. 2004 Jan;24(1):40-89 [14595672.001]

[Cites] J Biol Chem. 2003 Dec 12;278(50):50226-33 [14522978.001]

[Cites] Drug Resist Updat. 2004 Apr;7(2):97-110 [15158766.001]

[Cites] Cell Death Differ. 2004 Jul;11(7):737-46 [15002036.001]

[Cites] Cell Cycle. 2004 Mar;3(3):324-34 [14726646.001]

[Cites] Biochemistry. 1982 Dec 21;21(26):6628-33 [7159551.001]

[Cites] Antioxid Redox Signal. 2007 Jan;9(1):25-47 [17115886.001]

[Cites] Carcinogenesis. 2006 Dec;27(12):2538-49 [16777982.001]

[Cites] Semin Cancer Biol. 2006 Dec;16(6):452-65 [17056271.001]

[Cites] Semin Cancer Biol. 2006 Dec;16(6):420-6 [17092741.001]

[Cites] Cancer Res. 2006 Dec 1;66(23):11416-23 [17145888.001]

[Cites] Toxicol Appl Pharmacol. 2007 Jan 1;218(1):88-95 [17156807.001]

[Cites] Leukemia. 2000 Feb;14(2):262-70 [10673743.001]

[Cites] Nature. 2000 Mar 2;404(6773):42-9 [10716435.001]

[Cites] Annu Rev Biochem. 1985;54:237-71 [3896121.001]

[Cites] J Biol Chem. 1989 Aug 25;264(24):13963-6 [2668278.001]

[Cites] J Biol Chem. 1989 Oct 5;264(28):16502-6 [2674134.001]

[Cites] Biochem Pharmacol. 1992 Apr 1;43(7):1621-7 [1567483.001]

[Cites] Methods Enzymol. 1995;252:199-208 [7476354.001]

[Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6146-51 [8650234.001]

[Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3633-8 [9108029.001]

[Cites] J Biol Chem. 1998 Apr 10;273(15):8581-91 [9535831.001]

[Cites] EMBO J. 1998 May 1;17(9):2596-606 [9564042.001]

[Cites] Blood. 1999 Jan 1;93(1):268-77 [9864170.001]

[Cites] J Biol Chem. 1999 Feb 19;274(8):4722-34 [9988709.001]

[Cites] Blood. 1999 Sep 15;94(6):2102-11 [10477740.001]

[Cites] J Mol Biol. 1999 Oct 8;292(5):1003-16 [10512699.001]

[Cites] Chem Res Toxicol. 1999 Oct;12(10):924-30 [10525267.001]

[Cites] Anticancer Drugs. 2005 Feb;16(2):119-27 [15655408.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):673-8 [15637150.001]

[Cites] Blood. 2005 Feb 1;105(3):1237-45 [15466933.001]

[Cites] Antioxid Redox Signal. 2005 Mar-Apr;7(3-4):348-66 [15706083.001]

[Cites] J Clin Oncol. 2005 Apr 1;23(10):2396-410 [15800332.001]

[Cites] Annu Rev Pharmacol Toxicol. 2005;45:51-88 [15822171.001]

[Cites] Nat Methods. 2004 Oct;1(1):61-6 [15782154.001]

[Cites] Free Radic Biol Med. 2005 Jun 15;38(12):1543-52 [15917183.001]

[Cites] Oncogene. 2005 Jun 2;24(24):3853-63 [15824742.001]

[Cites] J Biol Chem. 2005 Jul 1;280(26):25284-90 [15879598.001]

[Cites] Hematology. 2005 Jun;10(3):205-13 [16019469.001]

[Cites] Free Radic Biol Med. 2005 Sep 1;39(5):696-703 [16085187.001]

[Cites] Front Biosci. 2006;11:300-12 [16146732.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15018-23 [16217027.001]

[Cites] Trends Mol Med. 2005 Dec;11(12):571-8 [16290020.001]

[Cites] Free Radic Biol Med. 2006 Jan 1;40(1):138-45 [16337887.001]

[Cites] J Biol Chem. 2006 Apr 21;281(16):10691-7 [16481328.001]

[Cites] Cancer Res. 2006 Apr 15;66(8):4410-8 [16618767.001]

[Cites] J Biol Chem. 2006 May 12;281(19):13005-8 [16565519.001]

[Cites] Mutat Res. 2006 Jun;612(3):215-46 [16574468.001]

[Cites] Biochem Biophys Res Commun. 2006 Jul 21;346(1):242-51 [16756956.001]

[Cites] Cancer Cell. 2006 Sep;10(3):175-6 [16959608.001]

[Cites] Antioxid Redox Signal. 2006 Sep-Oct;8(9-10):1881-90 [16987040.001]

[Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5854-9 [10801974.001]

[Cites] J Biol Chem. 2000 Jun 16;275(24):18121-8 [10849437.001]

[Cites] Eur J Biochem. 2000 Oct;267(20):6102-9 [11012661.001]

[Cites] Free Radic Biol Med. 2000 Aug;29(3-4):312-22 [11035260.001]

[Cites] J Pharmacol Exp Ther. 2001 Jan;296(1):1-6 [11123355.001]

[Cites] Blood. 2001 Jan 1;97(1):264-9 [11133770.001]

[Cites] Cell Mol Life Sci. 2000 Dec;57(13-14):1825-35 [11215509.001]

[Cites] J Physiol. 2001 Feb 15;531(Pt 1):1-11 [11179387.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3673-8 [11259642.001]

[Cites] Chem Res Toxicol. 2001 May;14(5):517-22 [11368549.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9533-8 [11481439.001]

[Cites] Toxicol Appl Pharmacol. 2001 Oct 15;176(2):127-44 [11601889.001]

[Cites] Free Radic Biol Med. 2001 Nov 15;31(10):1170-8 [11705695.001]

[Cites] Breast Cancer Res Treat. 2002 May;73(1):61-73 [12083632.001]

[Cites] Cancer Res. 2002 Jul 15;62(14):3893-903 [12124315.001]

[Cites] Clin Cancer Res. 2002 Dec;8(12):3658-68 [12473574.001]

[Cites] Cell Mol Life Sci. 2002 Nov;59(11):1972-82 [12530527.001]

[Cites] Science. 2003 May 30;300(5624):1439-43 [12775843.001]

(PMID = 17640917.001).

[ISSN] 0027-8424

[Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America

[ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Arsenicals; 0 / Enzyme Inhibitors; 0 / Oxides; EC 1.8.1.9 / Thioredoxin-Disulfide Reductase; GAN16C9B8O / Glutathione; S7V92P67HO / arsenic trioxide

[Other-IDs] NLM/ PMC1940330

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Determination of non-bilayer phospholipid arrangements and their antibodies in placentae and sera of patients with hypertensive disorders of pregnancy.

Antiphospholipid antibodies (APA) in circulation are also associated with vascular diseases.

In fact, the pathology of placentae from PE and Antiphospholipid syndrome patients is similar; atherosis, thrombosis and infarction, and endothelium activation represent the pathological mechanisms.

We identified a new antibody which recognizes non-bilayer phospholipid arrangements (NPA) in membrane models and in cell membranes in vivo, and which triggered an autoimmune-like disease in mice.

Results showed increased levels of NPA in the syncytiotrophoblast, extravillous cytotrophoblast, syncytial knots and the amnion epithelial cell membranes of the placenta, as well as increases in NPA and NPA antibodies in sera from HDP patients, when compared with controls.

[MeSH-major] Antibodies, Antiphospholipid / analysis. Membrane Lipids / analysis. Phospholipids / analysis. Placenta / chemistry. Pre-Eclampsia / etiology

Genetic Alliance. consumer health - Pregnancy.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16338467.001).

[ISSN] 0143-4004

[Journal-full-title] Placenta

[ISO-abbreviation] Placenta

[Language] eng

[Grant] United States / NICHD NIH HHS / HD / HD40363

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Membrane Lipids; 0 / Phospholipids

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Advances in management of acute promyelocytic leukemia with arsenic trioxide.

[MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17609904.001).

[ISSN] 1672-0415

[Journal-full-title] Chinese journal of integrative medicine

[ISO-abbreviation] Chin J Integr Med

[Language] eng

[Publication-type] Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Water-soluble CdTe quantum dots synthesized in aqueous solution have been conjugated with peptide LyP-1 using N-Succinimidyl 3-[2-pyridyldithio]-propionate (SPDP) as a cross-linking reagent.

Capillary electrophoresis (CE), UV-Vis absorption and photoluminescent (PL) spectra suggested that the peptide had been successfully linked to the QDs.

The QDs-peptides conjugates could specifically recognize the lung adenoma cancer cells (SPCA-1), but did not recognize promyelocytic leukemia cells (HL-60).

MedlinePlus Health Information. consumer health - Lung Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17713265.001).

[ISSN] 1001-5515

[Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi

[ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / LyP-1 protein, mouse; 0 / Oligopeptides; 0 / Peptides; 0 / Peptides, Cyclic; 99896-85-2 / arginyl-glycyl-aspartic acid

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] PML mediates IFN-alpha-induced apoptosis in myeloma by regulating TRAIL induction.

Interferon (IFN) induces expression of proapoptotic genes and has been used in the clinical treatment of multiple myeloma.

The promyelocytic leukemia (PML) gene is an IFN-induced target that encodes a tumor suppressor protein.

PML protein is typically localized within discrete speckled nuclear structures termed PML nuclear bodies (NBs).

Herein, we show that growth inhibition effects of IFN-alpha in myeloma cells correlate with PML NBs and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induction, whereas known IFN targets including signal transducer and activator of transcription-1 (STAT1), STAT3, p38, and Daxx cannot account for these differential responses.

RNAi silencing of PML blocks IFN-alpha-induced apoptosis in myeloma cells and correspondingly down-regulates TRAIL expression.

These results demonstrate that PML and TRAIL play important roles in IFN-induced apoptosis and identify TRAIL as a novel downstream transcriptional target of PML.

Identification of PML and PML NBs as effectors of IFN responses provides insights into mechanisms by which tumor cells exhibit resistance to this class of agents and may prove useful in assessing treatment regimens.

[MeSH-major] Apoptosis / drug effects. Interferon-alpha / pharmacology. Membrane Glycoproteins / physiology. Neoplasm Proteins / physiology. Nuclear Proteins / physiology. Transcription Factors / physiology. Tumor Necrosis Factor-alpha / physiology

[MeSH-minor] Apoptosis Regulatory Proteins. Cell Division / drug effects. Cell Line, Tumor. Humans. Leukemia, Promyelocytic, Acute. Multiple Myeloma. RNA, Small Interfering / genetics. TNF-Related Apoptosis-Inducing Ligand. Transfection. Tumor Suppressor Proteins

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15459016.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Interferon-alpha; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / RNA, Small Interfering; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Transcription Factors; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Suppressor Proteins; 143220-95-5 / PML protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

When cell-permeating fluorescent dyes were used as indicators of the generation of reactive oxygen species (ROS), we found that PAT treatment directly increased intracellular oxidative stress in human embryonic kidney (HEK293) and human promyelocytic leukemia (HL-60) cells.

Lipid peroxidation levels were also significantly increased in HL-60 cells and mouse kidney homogenates treated with PAT.

Pretreatment of HEK293 cells with Tiron, a free radical scavenger, reduced the phosphorylation levels of extracellular signal-regulated kinase (ERK) 1/2 elicited by PAT.

The ERK1/2 signaling pathway inhibitor, U0126, also significantly decreased the levels of ROS associated with PAT treatment.

Hazardous Substances Data Bank. PATULIN .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17090621.001).

[ISSN] 1096-6080

[Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology

[ISO-abbreviation] Toxicol. Sci.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Free Radical Scavengers; 0 / Reactive Oxygen Species; 95X2BV4W8R / Patulin; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adenovirus type 5 E4orf3 protein targets the Mre11 complex to cytoplasmic aggresomes.

Rearrangement of Mre11 and Rad50 by Ad5 E4orf3 is not dependent on interactions with Nbs1 or promyelocytic leukemia protein nuclear bodies.

COS Scholar Universe. author profiles.

Coriell Cell Repositories. culture/stock collections - Coriell Cell Repositories .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Virol. 1989 Jun;63(6):2605-15 [2724411.001]

[Cites] J Virol. 2005 Jun;79(11):6664-73 [15890904.001]

[Cites] EMBO J. 1990 Aug;9(8):2621-9 [2142453.001]

[Cites] J Struct Biol. 1990 May;103(3):280-9 [2261312.001]

[Cites] J Virol. 1991 Jan;65(1):424-9 [1824641.001]

[Cites] J Virol. 1992 May;66(5):3140-50 [1560540.001]

[Cites] Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):153-7 [8278357.001]

[Cites] Virology. 1999 Oct 25;263(2):307-12 [10544104.001]

[Cites] Science. 1999 Dec 3;286(5446):1888-93 [10583944.001]

[Cites] J Cell Physiol. 1994 Jul;160(1):47-60 [8021299.001]

[Cites] EMBO J. 1994 Nov 1;13(21):5075-85 [7957073.001]

[Cites] J Cell Biol. 1995 Oct;131(1):45-56 [7559785.001]

[Cites] Genes Dev. 1996 Jan 15;10(2):196-207 [8566753.001]

[Cites] J Virol. 1996 Sep;70(9):6323-35 [8709260.001]

[Cites] EMBO J. 1997 Jul 16;16(14):4276-84 [9250671.001]

[Cites] J Gen Virol. 1997 Sep;78 ( Pt 9):2131-8 [9291998.001]

[Cites] Curr Opin Cell Biol. 1998 Feb;10(1):52-9 [9484595.001]

[Cites] Cell. 1998 May 1;93(3):477-86 [9590181.001]

[Cites] J Cell Biol. 1998 Dec 28;143(7):1883-98 [9864362.001]

[Cites] J Virol. 1999 Mar;73(3):2253-62 [9971808.001]

[Cites] J Gen Virol. 1999 Apr;80 ( Pt 4):997-1008 [10211970.001]

[Cites] Cell. 1999 Dec 10;99(6):577-87 [10612394.001]

[Cites] Trends Cell Biol. 1999 Dec;9(12):M42-5 [10611680.001]

[Cites] J Virol. 2000 Dec;74(23):11407-12 [11070042.001]

[Cites] Trends Cell Biol. 2000 Dec;10(12):524-30 [11121744.001]

[Cites] Mol Cell Biol. 2001 Mar;21(6):2184-91 [11238951.001]

[Cites] Nat Genet. 2001 Apr;27(4):417-21 [11279524.001]

[Cites] J Cell Biol. 2001 Apr 30;153(3):449-55 [11331297.001]

[Cites] Gene. 2001 Oct 31;278(1-2):1-23 [11707318.001]

[Cites] J Virol. 2002 Feb;76(3):1475-87 [11773420.001]

[Cites] J Virol. 2002 May;76(9):4507-19 [11932416.001]

[Cites] Traffic. 2002 Jun;3(6):388-96 [12010457.001]

[Cites] Nature. 2002 Jul 18;418(6895):348-52 [12124628.001]

[Cites] J Gen Virol. 2003 Feb;84(Pt 2):259-68 [12560556.001]

[Cites] J Virol. 2003 May;77(9):5295-304 [12692231.001]

[Cites] EMBO J. 2003 Dec 15;22(24):6610-20 [14657032.001]

[Cites] J Virol. 2004 Jan;78(1):441-53 [14671124.001]

[Cites] Cell. 2003 Dec 12;115(6):727-38 [14675537.001]

[Cites] Nat Med. 2004 Jul;10 Suppl:S10-7 [15272267.001]

[Cites] J Virol. 2004 Sep;78(18):9924-35 [15331726.001]

[Cites] Exp Cell Res. 2004 Oct 1;299(2):486-97 [15350546.001]

[Cites] J Mol Biol. 1982 Dec 15;162(3):565-83 [7166756.001]

[Cites] Eur J Cell Biol. 1984 Jul;34(2):313-22 [6236979.001]

[Cites] J Virol. 1985 Oct;56(1):250-7 [4032537.001]

[Cites] Virology. 1985 Apr 15;142(1):44-58 [2932843.001]

[Cites] J Virol. 1986 Mar;57(3):833-8 [3485200.001]

[Cites] Oncogene. 1988 Jun;2(6):579-84 [3290806.001]

[Cites] J Cell Biol. 1999 Sep 20;146(6):1239-54 [10491388.001]

[Cites] Oncogene. 2005 Jan 6;24(1):55-64 [15480414.001]

[Cites] J Virol. 2005 May;79(10):6207-15 [15858005.001]

[Cites] Virology. 1990 Feb;174(2):345-53 [2137659.001]

(PMID = 16103189.001).

[ISSN] 0022-538X

[Journal-full-title] Journal of virology

[ISO-abbreviation] J. Virol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA097093; United States / NIAID NIH HHS / AI / AI43341; United States / NCI NIH HHS / CA / CA97093

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Adenovirus E4 Proteins; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / MRE11A protein, human; 0 / Multiprotein Complexes; 0 / NBN protein, human; 0 / Nuclear Proteins; 0 / Rad50 protein, human; 0 / Tubulin; EC 6.5.1.- / DNA Repair Enzymes

[Other-IDs] NLM/ PMC1193610

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Antiphospholipid syndrome. Current insights into laboratory diagnosis and pathophysiology.

The antiphospholipid syndrome (APS) is a non-inflammatory autoimmune disease characterized by the presence of antiphospholipid antibodies (aPL) in the plasma of patients with vascular thrombosis, recurrent complications of pregnancy, or both (1, 2).

The presence of aPL in plasma of patients can be detected with either a prolongation of phospholipid dependent coagulation tests (lupus anticoagulant, LAC), or with solid phase immune assays against the protein beta2-glycoprotein I (beta2-GPI) or the phospholipid cardiolipin (anti-beta2-GPI antibody ELISA and anti-cardiolipin antibody ELISA, respectively) (3).

To solve this dispute, an international consensus meeting was organized in Sapporo in 1999 to formulate classification criteria for patients with the antiphospholipid syndrome (4).

This is very unfortunate because the specificity of the different aPL assays to detect the clinical manifestations that characterize APS are disputable.

One of the aims of defining the criteria was to initiate studies to determine the value of the different anti-phospholipid antibody assays to serve as biomarker for the risk of thrombosis and pregnancy morbidity.

[MeSH-major] Antiphospholipid Syndrome / diagnosis. Antiphospholipid Syndrome / physiopathology

[MeSH-minor] Antibodies, Antiphospholipid / blood. Antibodies, Antiphospholipid / physiology. Clinical Laboratory Techniques. Female. Humans. Pregnancy. Pregnancy Complications / blood

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20680233.001).

[ISSN] 0720-9355

[Journal-full-title] Hämostaseologie

[ISO-abbreviation] Hamostaseologie

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Blood lactate concentration [LAC] is considered a useful indicator of disease severity in horses.

HYPOTHESIS: It was hypothesized that results from a POC lactate monitor would be in agreement with a laboratory-based measurement of [LAC].

[LAC] was measured with whole blood (AWB) and plasma (APL) by means of a POC monitor (Accutrend) and compared with results from whole blood measured by a laboratory blood gas analyzer (NOVA).

Agreement (p +/- SE) was closest between APL and NOVA (0.97 +/- 0.01); an average observed difference of 0.15 +/- 0.89 (mean +/- SD) and 95% limits of agreement (LOA) -1.89, 1.59 also were found.

CONCLUSIONS AND CLINICAL IMPORTANCE: Results indicate close agreement between NOVA and the POC monitor when [LAC] was measured with plasma.

MedlinePlus Health Information. consumer health - Emergency Medical Services.

Hazardous Substances Data Bank. LACTIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17939569.001).

[ISSN] 0891-6640

[Journal-full-title] Journal of veterinary internal medicine

[ISO-abbreviation] J. Vet. Intern. Med.

[Language] ENG

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 33X04XA5AT / Lactic Acid

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome.

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by arterial and venous thrombosis, recurrent abortions, and antiphospholipid antibodies (aPL).

However, it is possible to find patients with clinical signs of APS who persistently test negative for aPL (seronegative APS, or SN-APS).

We tested sera from patients with SN-APS with a proteomic approach by analyzing endothelial cell-surface membrane proteins.

Our results prompt to identify vimentin as a "new" cofactor for aPL, which may represent a useful tool mainly in SN-APS patients.

[MeSH-major] Antiphospholipid Syndrome / diagnosis. Autoantibodies / immunology. Cardiolipins / immunology. Vimentin / immunology

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Blood. 2010 Oct 21;116(16):2867-9 [20966174.001]

(PMID = 20634382.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Autoantibodies; 0 / Cardiolipins; 0 / NF-kappa B; 0 / Vimentin; EC 2.7.11.1 / IRAK1 protein, human; EC 2.7.11.1 / Interleukin-1 Receptor-Associated Kinases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Venous thrombosis and pulmonary embolism in a child with pneumonia due to Mycoplasma pneumoniae.

A 13-year-old boy with Mycoplasma pneumoniae pulmonary infection developed deep vein thrombosis and pulmonary embolism.

He was found to have protein S deficiency and transient antiphospholipid antibodies.

Though uncommon, it is important to consider venous thromboembolic disease in children whose clinical course is atypically severe.

[MeSH-major] Lupus Erythematosus, Systemic / complications. Pneumonia, Mycoplasma / complications. Pulmonary Embolism / etiology. Venous Thrombosis / etiology

[MeSH-minor] Adolescent. Anticoagulants / therapeutic use. Antiphospholipid Syndrome / complications. Antiphospholipid Syndrome / immunology. Heparin / therapeutic use. Humans. Male. Protein S Deficiency / complications. Protein S Deficiency / immunology. Warfarin / therapeutic use

Genetic Alliance. consumer health - Embolism.

Genetic Alliance. consumer health - Thrombosis.

MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.

MedlinePlus Health Information. consumer health - Lupus.

MedlinePlus Health Information. consumer health - Pulmonary Embolism.

Hazardous Substances Data Bank. WARFARIN .

Hazardous Substances Data Bank. HEPARIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19806855.001).

[ISSN] 1943-4693

[Journal-full-title] Journal of the National Medical Association

[ISO-abbreviation] J Natl Med Assoc

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Anticoagulants; 5Q7ZVV76EI / Warfarin; 9005-49-6 / Heparin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Focal seizures after treatment with fluvastatin in a patient with a history of catastrophic antiphospholipid syndrome.

The symptoms appeared one day after start of the treatment with fluvastatin (40 mg) administered in order to diminish the endothelial activation induced by antiphospholipid antibodies (aPL).

The patient suffered from severe manifestations of the antiphospholipid syndrome (APS) including Catastrophic Antiphospholipid Syndrome (CAPS, Asherson's syndrome).

[MeSH-major] Antiphospholipid Syndrome / complications. Epilepsies, Partial / chemically induced. Fatty Acids, Monounsaturated / adverse effects. Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects. Indoles / adverse effects. Seizures / chemically induced

Genetic Alliance. consumer health - Catastrophic Antiphospholipid Syndrome.

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

Genetic Alliance. consumer health - Seizures.

MedlinePlus Health Information. consumer health - Seizures.

MedlinePlus Health Information. consumer health - Statins.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16111706.001).

[ISSN] 0022-510X

[Journal-full-title] Journal of the neurological sciences

[ISO-abbreviation] J. Neurol. Sci.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Fatty Acids, Monounsaturated; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Indoles; 4L066368AS / fluvastatin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prevalence and clinicopathologic findings of antiphospholipid syndrome nephropathy in Thai systemic lupus erythematosus patients who underwent renal biopsies.

AIM: To determine the prevalence of antiphospholipid syndrome nephropathy (APSN) in Thai systemic lupus erythematosus (SLE) patients who underwent renal biopsy and to compare the relationship of renal histopathology and other significant clinical parameters between SLE patients with and without APSN.

METHODS: A retrospective analysis was undertaken in systemic lupus erythematosus patients (n = 150, 44 <15 years old, 106 0e;15 years old) who underwent renal biopsy.

The specimens were evaluated for histological features of APSN and other significant clinical parameters.

The result of antiphospholipid antibodies, clinical course, and renal function from chart review were analysed.

RESULTS: The prevalence of APSN in systemic lupus erythematosus patients who underwent renal biopsies was 34% (16% in <15-year-old group, 41.5% in > or =15-year-old group).

APSN was associated with more severe hypertension (P = 0.002 for systolic and P = 0.004 for diastolic blood pressure), acute renal failure (P = 0.003), persistent heavy proteinuria (P < 0.001 for 4+ proteinuria), severe lupus nephritis (class III and IV, P = 0.014, high activity and chronicity indices, P < 0.001) and a tendency to progress to end-stage renal disease.

[MeSH-major] Antiphospholipid Syndrome / complications. Antiphospholipid Syndrome / epidemiology. Kidney / pathology. Kidney Diseases / etiology. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / physiopathology

[MeSH-minor] Adolescent. Adult. Biopsy. Child. Child, Preschool. Chronic Disease. Disease Progression. Female. Humans. Infant. Kidney Failure, Chronic / etiology. Male. Middle Aged. Prevalence. Retrospective Studies. Severity of Illness Index. Thailand

Genetic Alliance. consumer health - Lupus.

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

Genetic Alliance. consumer health - Systemic lupus erythematosus.

MedlinePlus Health Information. consumer health - Kidney Diseases.

MedlinePlus Health Information. consumer health - Lupus.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17803471.001).

[ISSN] 1320-5358

[Journal-full-title] Nephrology (Carlton, Vic.)

[ISO-abbreviation] Nephrology (Carlton)

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Australia

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Lung adenocarcinoma and antiphospholipid antibodies.

Thrombosis is a frequent finding in cancer patients, being referred to as a poor prognostic factor.

A number of studies have demonstrated the presence of antiphospholipid antibodies (aPL) in cancer patients, suggesting a potential role in tumor-associated thrombosis.

A prospective analysis has been performed in a group of lung adenocarcinoma patients in respect to the presence of aPL and thrombotic manifestations.

On the other hand, patients that displayed IgM anti-beta2-glycoprotein I (abeta2GPI) (22/80) showed an unexpected decrease in thrombosis risk (2/22, with IgM abeta2GPI vs 18/58, without IgM abeta2GPI RR=0.29; p=0.04).

Considerations on the mechanisms that link cancer, thrombosis and aPL are discussed in this article.

[MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / immunology. Antibodies, Antiphospholipid / blood. Lung Neoplasms / diagnosis. Lung Neoplasms / immunology

MedlinePlus Health Information. consumer health - Lung Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19185619.001).

[ISSN] 1873-0183

[Journal-full-title] Autoimmunity reviews

[ISO-abbreviation] Autoimmun Rev

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Autoantibodies; 0 / Immunoglobulin M; 0 / Lupus Coagulation Inhibitor; 0 / beta 2-Glycoprotein I

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Tamibarotene is a new synthetic retinoid drug recently approved for relapsed or refractory acute promyelocytic leukemia (APL) in Japan.

It is a specific agonist for retinoic acid receptor alpha/beta.

Compared to all-trans retinoic acid (ATRA), a natural retinoid indicated for a first-line treatment of APL, tamibarotene is chemically more stable and several times more potent as an inducer of differentiation in promyelocytic leukemia cells.

In contrast to ATRA, whose plasma concentration declines considerably during daily administration, tamibarotene sustains plasma level probably due to a lower affinity for cellular retinoic acid binding protein.

Furthermore, adverse side effects were milder than those of ATRA in clinical trials.

Clinical trials held in Japan showed that tamibarotene had efficacy in APL patients who had relapsed from ATRA-induced complete remission.

Tamibarotene is being investigated for treatment of multiple myeloma and Crohn's disease in clinical trials.

This review focuses on tamibarotene's mechanisms of action, chemical properties, pharmacokinetics and its use in APL as well as its potential use in various disorders.

[MeSH-major] Antineoplastic Agents / therapeutic use. Benzoates / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Tetrahydronaphthalenes / therapeutic use

[MeSH-minor] Animals. Controlled Clinical Trials as Topic. Drug Evaluation, Preclinical. Humans

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

SciCrunch. DrugBank: Data: Chemical .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2007 Prous Science.

(PMID = 17925887.001).

[ISSN] 1699-3993

[Journal-full-title] Drugs of today (Barcelona, Spain : 1998)

[ISO-abbreviation] Drugs Today

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Spain

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoates; 0 / Tetrahydronaphthalenes; 08V52GZ3H9 / tamibarotene

[Number-of-references] 38

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.

We present here two patients treated with mitoxantrone for MS who subsequently developed acute promyelocytic leukemia (APL).

These constitute, to our knowledge, the eighth and ninth reports of APL in patients treated with mitoxantrone for MS.

Topoisomerase 2 inhibitors are associated with therapy-related acute myeloid leukemia (t-AML) with 11q23 abnormalities, but therapy-related APL (t-APL) is less common, and documentation of nine cases of t-APL after mitoxantrone therapy for MS suggests a specific association.

[MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Promyelocytic, Acute / chemically induced. Mitoxantrone / adverse effects. Multiple Sclerosis / drug therapy

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Multiple Sclerosis.

MedlinePlus Health Information. consumer health - Multiple Sclerosis.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. NOVANTRONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] Cancer Genet Cytogenet. 2008 Oct 15;186(2):130

(PMID = 18406875.001).

[ISSN] 0165-4608

[Journal-full-title] Cancer genetics and cytogenetics

[ISO-abbreviation] Cancer Genet. Cytogenet.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; BZ114NVM5P / Mitoxantrone

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [In vitro study of the effects of CDA-II combined with cAMP on apoptosis induction in retinoic acid resistant acute promyelocytic leukemia cells].

OBJECTIVE: To investigate the effects of CDA-II alone or combined with cAMP on the retinoic acid (RA)-resistant acute promyelocytic leukemia (APL) cells.

The level of Bcl-2 was detected by flow cytometry, DNA "ladder" was detected by agarose-electrophoresis.

RESULTS: CDA-II could induce NB4-R2 cell apoptosis through decreasing the level of cellular anti-apoptotic protein Bcl-2. cAMP could significantly enhance the role of CDA-II.

Bcl-2 positive cell rates decreased to (15.1 +/- 4.8)% and (7.3 +/- 2.9)% in NB4-R2 cells treated with 1 mg/ml CDA-II plus 100 micromol/L cAMP for 48 h and 72 h, respectively.

CONCLUSIONS: CDA-II combined with cAMP could exert potent apoptotic effect on RA-resistant APL cells.

[MeSH-major] Cyclic AMP / pharmacology. Leukemia, Promyelocytic, Acute / pathology. Peptides / pharmacology. Phenylacetates / pharmacology. Tretinoin / pharmacology

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19175987.001).

[ISSN] 0253-2727

[Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Antigens, CD11c; 0 / Peptides; 0 / Phenylacetates; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / cell differentiation agent II; 5688UTC01R / Tretinoin; E0399OZS9N / Cyclic AMP

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A case of antiphospholipid syndrome presenting with pulmonary truncus and main pulmonary artery thrombosis.

In patients with antiphospholipid syndrome (APS), thromboembolism and pulmonary hypertension are the most common pulmonary manifestations.

Thrombotic obstruction at the level of the main and/or proximal pulmonary arteries is rare.

We report a 40-year-old woman without any history of previous arterial and/or venous thrombosis who presented with severe dyspnea and was found to have pulmonary hypertension and positivity for anticardiolipin antibodies.

Computed tomography revealed pulmonary truncus thrombosis extending to both right and left pulmonary arteries.

This is the first reported case with thrombosis of pulmonary truncus and main pulmonary arteries concurrent with APS.

[MeSH-major] Antiphospholipid Syndrome / pathology. Pulmonary Artery / pathology. Pulmonary Embolism / pathology

[MeSH-minor] Adult. Antibodies, Anticardiolipin / blood. Diagnosis, Differential. Echocardiography. Fatal Outcome. Female. Humans. Hypertension, Pulmonary / etiology. Hypertension, Pulmonary / pathology. Radiography, Thoracic. Tomography, X-Ray Computed

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

Genetic Alliance. consumer health - Thrombosis.

MedlinePlus Health Information. consumer health - Pulmonary Embolism.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Thorac Surg. 1998 Dec;66(6):1919-24 [9930469.001]

[Cites] J Rheumatol. 1996 Apr;23 (4):772-5 [8730145.001]

[Cites] Arthritis Rheum. 1992 Jun;35(6):700-5 [1599524.001]

[Cites] Am J Med. 1994 Jan;96(1):3-9 [8304360.001]

[Cites] Med Clin (Barc). 1996 Apr 6;106(13):498-500 [8992132.001]

[Cites] Baillieres Clin Rheumatol. 1998 Aug;12(3):477-93 [9890108.001]

[Cites] Int J Biochem Cell Biol. 2003 Jul;35(7):1015-20 [12672470.001]

[Cites] Ann Thorac Surg. 1996 Nov;62(5):1255-9; discussion 1259-60 [8893554.001]

[Cites] Br J Haematol. 2000 Jun;109(4):704-15 [10929019.001]

[Cites] Jpn Circ J. 1997 Nov;61(11):958-64 [9391866.001]

[Cites] J Rheumatol. 1995 Jan;22(1):62-6 [7699684.001]

[Cites] Surg Today. 1992;22(6):548-52 [1472796.001]

[Cites] Arthritis Rheum. 2002 Apr;46(4):1019-27 [11953980.001]

[Cites] Medicine (Baltimore). 1998 May;77(3):195-207 [9653431.001]

(PMID = 15378261.001).

[ISSN] 0172-8172

[Journal-full-title] Rheumatology international

[ISO-abbreviation] Rheumatol. Int.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Antibodies, Anticardiolipin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anti-cardiolipin and anti-beta2-glycoprotein I antibodies: performance of new commercial ELISA kits.

Antiphospholipid antibodies (aPL) are known to be pathogenic in experimental models and are predictive of thrombosis and miscarriages in patients, so it is important to correctly evaluate their presence for identifying patients at risk.

Despite many years of work, the standardization of aPL ELISA remains an open problem, so evaluation of newly introduced commercial preparations is mandatory.

A total of 80 sera were collected (10 primary antiphospholipid syndromes (APSs), 10 APSs associated with systemic lupus erythematosus, 20 infectious diseases, 20 rheumatoid arthritis and 20 normal blood donors) and tested for IgG/IgM anti-cardiolipin and anti-beta2GPI antibodies on commercial ELISA kits (ETI) by DiaSorin and on home-made ELISA.

Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17785342.001).

[ISSN] 0077-8923

[Journal-full-title] Annals of the New York Academy of Sciences

[ISO-abbreviation] Ann. N. Y. Acad. Sci.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies; 0 / Cardiolipins; 0 / beta 2-Glycoprotein I

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Multifocal electroretinography in ophtalmological symptoms in patients with antiphospholipid syndrome].

The paper describes the first experience in using multifocal electroretinography (mfERG) in patients with antiphospholipid syndrome (APS).

In the latter, thrombogenesis is mosaic in most cases so the techniques providing a spatial imaging of the pathological process is of interest in the examination of patients with this disease.

[MeSH-major] Antiphospholipid Syndrome / physiopathology. Electroretinography / methods. Retina / physiopathology. Retinal Diseases / physiopathology

[MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Humans. Middle Aged. Visual Field Tests. Visual Fields / physiology. Young Adult

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

MedlinePlus Health Information. consumer health - Retinal Disorders.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19284102.001).

[ISSN] 0042-465X

[Journal-full-title] Vestnik oftalmologii

[ISO-abbreviation] Vestn Oftalmol

[Language] rus

[Publication-type] Comparative Study; English Abstract; Journal Article

[Publication-country] Russia (Federation)

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Antiphospholipid syndrome patients display reduced titers of soluble CD21 in their sera irrespective of circulating anti-beta2-glycoprotein-I autoantibodies.

The sCD21 is able to bind all known ligands such as CD23, sCD23, Epstein-Barr virus and C3d in immune complexes.

Here, we show the serum levels of sCD21 in sera the of antiphospholipid syndrome (APS) patients.

Antiphospholipid syndrome is an autoimmune disorder in which autoantibodies cause heart attack, stroke and miscarriage.

Antiphospholipid syndrome may appear as primary or in association with systemic lupus erythromatosus (SLE) and other autoimmune diseases.

Here, we ask whether APS patients have different sCD21 titers compared to healthy persons and whether sCD21 levels correlate with the presence of anti-beta2-GPI autoantibodies.

We show that autoimmune APS patients have significantly reduced amounts of sCD21 in their sera, irrespective of the presence of anti-beta2-GPI autoantibodies.

In our APS patients cohort additional SLE, vasculities, DVT (deep vein thrombosis), fetal loss or thrombosis did not correlate to the reduced level of sCD21.

[MeSH-major] Antiphospholipid Syndrome / blood. Autoantibodies / blood. Receptors, Complement 3d / blood. beta 2-Glycoprotein I / immunology

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Immunol. 1985 Oct;135(4):2687-94 [2411809.001]

[Cites] Lupus. 2003;12(7):497-8 [12892386.001]

[Cites] Int Immunol. 1998 Oct;10(10):1459-66 [9796912.001]

[Cites] J Immunol. 2005 Mar 15;174(6):3264-72 [15749857.001]

[Cites] Eur J Immunol. 2003 Sep;33(9):2391-7 [12938215.001]

[Cites] Circulation. 1998 Mar 10;97(9):900-6 [9521339.001]

[Cites] J Rheumatol. 1994 Jan;21(1):100-4 [8151562.001]

[Cites] Science. 1991 Oct 4;254(5028):102-5 [1718035.001]

[Cites] Eur J Immunol. 1988 Aug;18(8):1299-302 [2970972.001]

[Cites] J Immunol. 1989 Nov 15;143(10):3200-6 [2478621.001]

[Cites] Proc Natl Acad Sci U S A. 1984 Feb;81(3):881-5 [6230668.001]

[Cites] Proc Natl Acad Sci U S A. 1984 Jul;81(14):4510-4 [6087328.001]

[Cites] Lancet. 1990 Jun 30;335(8705):1544-7 [1972485.001]

[Cites] Science. 2001 Jun 1;292(5522):1725-8 [11387479.001]

[Cites] Trends Immunol. 2005 May;26(5):275-81 [15866241.001]

[Cites] J Immunol. 1998 Nov 15;161(10):5303-12 [9820503.001]

[Cites] Biochem Soc Trans. 2002 Nov;30(Pt 6):983-9 [12440958.001]

[Cites] J Clin Invest. 2002 Mar;109(6):797-804 [11901188.001]

[Cites] J Biol Chem. 1990 Jul 25;265(21):12293-9 [1695627.001]

[Cites] J Immunol. 2002 Jun 15;168(12):6279-85 [12055242.001]

[Cites] Rheumatology (Oxford). 2004 Feb;43(2):186-90 [12867574.001]

[Cites] J Biol Chem. 1989 Dec 5;264(34):20576-82 [2555366.001]

[Cites] J Immunol. 1998 Nov 1;161(9):4549-54 [9794381.001]

[Cites] Complement. 1987;4(2):87-98 [3497773.001]

[Cites] Scand J Immunol. 2004 Dec;60(6):625-30 [15584974.001]

[Cites] J Immunol. 1992 Aug 1;149(3):768-74 [1386093.001]

[Cites] J Immunol. 1991 Feb 1;146(3):865-9 [1703182.001]

[Cites] J Immunol Methods. 2002 Dec 1;270(1):11-8 [12379334.001]

[Cites] Clin Exp Immunol. 1993 Aug;93(2):195-9 [8348744.001]

[Cites] Immunobiology. 2002 Dec;206(5):528-36 [12607728.001]

[Cites] Clin Exp Immunol. 1991 Apr;84(1):16-22 [1849806.001]

[Cites] Immunol Lett. 1989 Jan 31;20(2):103-9 [2523865.001]

[Cites] Clin Lab Med. 1992 Mar;12(1):41-59 [1563240.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5164-8 [10220436.001]

[Cites] Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3069-73 [2014226.001]

[Cites] Nature. 1992 Aug 6;358(6386):505-7 [1386409.001]

(PMID = 18172655.001).

[ISSN] 0172-8172

[Journal-full-title] Rheumatology international

[ISO-abbreviation] Rheumatol. Int.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Autoantibodies; 0 / Receptors, Complement 3d; 0 / beta 2-Glycoprotein I

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Mitral valve replacement for mitral valve stenosis and insufficiency in a patient with antiphospholipid syndrome and systemic lupus erythematosus; report of a case].

She was previously diagnosed as antiphospholipid syndrome (APS) because of previous pregnancy morbidity and cerebral infarction.

[MeSH-major] Antiphospholipid Syndrome / complications. Heart Valve Prosthesis Implantation. Lupus Erythematosus, Systemic / complications. Mitral Valve Insufficiency / surgery. Mitral Valve Stenosis / surgery

Genetic Alliance. consumer health - Lupus.

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

Genetic Alliance. consumer health - Systemic lupus erythematosus.

MedlinePlus Health Information. consumer health - Lupus.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21174670.001).

[ISSN] 0021-5252

[Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery

[ISO-abbreviation] Kyobu Geka

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We have cloned the atypical PKC from Aplysia, PKC Apl III.

Instead, over-expression of PKC Apl III in Aplysia sensory neurons leads to production of a PKM fragment of PKC Apl III.

Moreover, nervous system enriched spliced forms of PKC Apl III show enhanced cleavage.

PKC Apl III could also be activated through phosphorylation downstream of phosphoinositide 3-kinase.

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19302474.001).

[ISSN] 1471-4159

[Journal-full-title] Journal of neurochemistry

[ISO-abbreviation] J. Neurochem.

[Language] eng

[Grant] Canada / Canadian Institutes of Health Research / / 12046

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 333DO1RDJY / Serotonin; 9007-49-2 / DNA; EC 2.7.11.13 / Protein Kinase C; EC 3.4.22.- / Calpain

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Antiphospholipid syndrome: modern problems].

The article describes the historical aspects of the formation of the notion antiphospholipid syndrome (AFS) as well as the development of the conception of its clinical symptoms and laboratory tests confirming the diagnosis.

Special attention is paid to the modern interpretation of the notion of AFS, which excludes a number of clinical symptoms and laboratory tests and defines more clearly the use of the rest of clinical and laboratory signs.

Theoretical concepts of the pathogenetic mechanisms of the development of this disease and its association with congenital thrombofilias are adduced.

[MeSH-major] Antiphospholipid Syndrome / physiopathology

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18219947.001).

[ISSN] 0023-2149

[Journal-full-title] Klinicheskaia meditsina

[ISO-abbreviation] Klin Med (Mosk)

[Language] rus

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Russia (Federation)

[Number-of-references] 29

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Hypomethylation of DNA repetitive elements is a common finding in cancer, but very little is known about the DNA methylation changes of different types of DNA repetitive elements, such as interspersed repeats (LINE1 and Alu Yb8) and tandem repeats (Sat-alpha, NBL-2 and D4Z4).

In all we studied 10 different tissues from four individuals undergoing autopsy, 34 paired normal and tumor tissues from patients with bladder cancer, 58 patients with chronic myelogenous leukemia and 23 patients with acute promyelocytic leukemia.

In bladder cancer we found clear hypomethylation of LINE1, Alu Yb8, Sat-alpha and NBL-2.

Conversely, we found an increase in the DNA methylation levels of D4Z4 from normal to cancer.

In contrast leukemia showed no significant changes in the DNA methylation of LINE1 and Alu Yb8, but DNA methylation increases in NBL-2 and D4Z4 tandem repeats.

Our findings show that the changes in DNA methylation levels of individual DNA repetitive elements are unique for each repetitive element, which may reflect distinct epigenetic factors and may have important implications in the use of DNA methylation of repetitive elements as global DNA methylation biomarkers.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Crit Rev Oncol Hematol. 1999 Sep;32(1):31-43 [10586353.001]

[Cites] Nucleic Acids Res. 2008 Apr;36(7):2196-207 [18281700.001]

[Cites] Nature. 2001 Feb 15;409(6822):860-921 [11237011.001]

[Cites] Oncogene. 2002 Aug 12;21(35):5400-13 [12154403.001]

[Cites] Science. 2003 Apr 18;300(5618):489-92 [12702876.001]

[Cites] Nucleic Acids Res. 2004;32(3):e38 [14973332.001]

[Cites] Blood. 2004 Mar 1;103(5):1635-40 [14604977.001]

[Cites] Cancer Res. 1988 Mar 1;48(5):1159-61 [3342396.001]

[Cites] Nature. 1988 May 5;333(6168):87-90 [2834650.001]

[Cites] Cancer Res. 1992 Feb 1;52(3):643-5 [1310068.001]

[Cites] Cancer Res. 1996 Dec 15;56(24):5698-703 [8971178.001]

[Cites] Nature. 1998 May 7;393(6680):68-72 [9590690.001]

[Cites] Int J Cancer. 1998 Sep 11;77(6):833-8 [9714050.001]

[Cites] Nat Genet. 1998 Oct;20(2):116-7 [9771701.001]

[Cites] Mutat Res. 1999 Jan 25;423(1-2):91-101 [10029684.001]

[Cites] Oncogene. 2004 Nov 18;23(54):8841-6 [15480421.001]

[Cites] Nat Rev Cancer. 2004 Dec;4(12):988-93 [15573120.001]

[Cites] J Clin Oncol. 2005 Jun 10;23(17):3948-56 [15883410.001]

[Cites] Cancer Biol Ther. 2005 Apr;4(4):440-8 [15846090.001]

[Cites] Oncogene. 2005 Nov 3;24(48):7213-23 [16170379.001]

[Cites] Mol Cancer Res. 2005 Nov;3(11):617-26 [16317087.001]

[Cites] Nucleic Acids Res. 2005;33(21):6823-36 [16326863.001]

[Cites] Cancer Res. 2006 May 15;66(10):5495-503 [16707479.001]

[Cites] Cancer Res. 2006 Sep 1;66(17):8469-76 [16951158.001]

[Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]

[Cites] Cancer Res. 2007 Feb 1;67(3):876-80 [17283117.001]

[Cites] Nat Rev Genet. 2007 Apr;8(4):253-62 [17363974.001]

[Cites] Br J Haematol. 2007 Sep;138(5):616-23 [17686055.001]

[Cites] Oncogene. 2008 Jan 10;27(3):404-8 [17621273.001]

[Cites] Leuk Res. 2008 Mar;32(3):487-90 [17765966.001]

[Cites] Nature. 2008 Mar 6;452(7183):45-50 [18322525.001]

[Cites] Hum Mol Genet. 2000 Mar 1;9(4):597-604 [10699183.001]

(PMID = 19437537.001).

[ISSN] 1097-0215

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P01 CA086871; United States / NIEHS NIH HHS / ES / P30 ES007048; United States / NIEHS NIH HHS / ES / 5P30ES07048; United States / NCI NIH HHS / CA / P01 CA86871

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Other-IDs] NLM/ NIHMS587075; NLM/ PMC4086885

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Does acute promyelocytic leukemia in Indian patients have biology different from the West?

Acute promyelocytic leukemia (APML) is a well-characterized malignancy with typical clinico-hematological and molecular features.

This study was conducted to determine the clinico-hematological profile of APML in India.

Thirty-five patients with APML presenting to Hematology Department, AIIMS, New Delhi, between July 2003 and June 2005 were evaluated for presenting clinical features, hemogram, peripheral smear, bone marrow morphology and cytochemistry.

Reverse transcriptase PCR (RT-PCR) for PML-RARalpha was done in all cases.

Male-to-female ratio was 0.9:1 (males--17 and females--18) with median age 25 years (range 11-57 years).

RT-PCR showed PML-RARalpha in 33/35 cases with the bcr3 isoform being present in 24/33 positive cases (72.7%).

The two cases negative for PML-RARalpha showed typical morphology and responded to ATRA.

APML in India has certain unusual features, which may reflect a different biology.

[MeSH-major] Leukemia, Promyelocytic, Acute / pathology

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18723985.001).

[ISSN] 0377-4929

[Journal-full-title] Indian journal of pathology & microbiology

[ISO-abbreviation] Indian J Pathol Microbiol

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Chemical-registry-number] 0 / Azo Compounds; 0 / Naphthalenes; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 9YDL1Q990E / Sudan Black B; EC 1.11.1.7 / Peroxidase; EC 3.1.- / Esterases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Atypical onset of antiphospholipid syndrome in pregnancy: a case report.

BACKGROUND: We present a case of an atypical onset of antiphospholipid syndrome (APS).

After 1 month, laboratory tests revealed high level of antiphospholipid antibodies.

After 6 weeks, antiphospholipid antibodies, tested again, result positive.

CONCLUSION: Antiphospholipid antibodies often cause pregnancy complications, but, to our knowledge, this is the first report of an association of antiphospholipid antibodies, with cerebral cavernoma thrombosis and early onset HELLP syndrome.

[MeSH-major] Antiphospholipid Syndrome / complications. Pregnancy Complications, Hematologic

[MeSH-minor] Abortion, Spontaneous. Adult. Antibodies, Antiphospholipid / blood. Cerebral Hemorrhage / complications. Cerebral Hemorrhage / diagnosis. Cerebral Hemorrhage / surgery. Female. HELLP Syndrome / complications. HELLP Syndrome / diagnosis. Humans. Pregnancy. Prognosis. Risk Factors. Thrombosis / complications. Thrombosis / diagnosis

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

Genetic Alliance. consumer health - Pregnancy.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15733974.001).

[ISSN] 0049-3848

[Journal-full-title] Thrombosis research

[ISO-abbreviation] Thromb. Res.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Here, a causal relationship among redox state, granulocytic differentiation induced by all-trans retinoic acid (RA) or dibutyryl cAMP (dbcAMP) and apoptosis have been studied in the human acute promyelocytic leukaemia HL-60 cells.

The modulation of intracellular reactive oxygen species levels by D: , L: -buthionine-(S, R) sulfoximide (BSO), and N: -acetyl-L: -cysteine (NAC) caused inducer- and time-dependent or stage-specific effects on HL-60 cell growth inhibition, differentiation and subsequent apoptosis.

Hazardous Substances Data Bank. N-ACETYLCYSTEINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Biol Chem. 1991 Apr 5;266(10):6188-94 [2007576.001]

[Cites] Cell Death Differ. 1999 Jul;6(7):698-709 [10453081.001]

[Cites] Free Radic Biol Med. 1989;6(6):593-7 [2546864.001]

[Cites] Cancer Res. 1994 Apr 1;54(7):1707-14 [7511048.001]

[Cites] J Biol Chem. 1998 Aug 28;273(35):22833-40 [9712918.001]

[Cites] Cancer Res. 1991 Feb 1;51(3):794-8 [1846317.001]

[Cites] Leuk Res. 1994 Jul;18(7):523-30 [8022202.001]

[Cites] Oncogene. 1999 Nov 22;18(49):6910-24 [10602466.001]

[Cites] J Cell Physiol. 1991 Jan;146(1):73-80 [1846637.001]

[Cites] Biochem Pharmacol. 1998 Jun 1;55(11):1747-58 [9714292.001]

[Cites] Free Radic Biol Med. 2000 May 1;28(9):1317-27 [10924851.001]

[Cites] J Clin Invest. 2001 Feb;107(3):241-6 [11160144.001]

[Cites] Cell Physiol Biochem. 2001;11(4):173-86 [11509825.001]

[Cites] Blood. 1992 Aug 1;80(3):788-94 [1379088.001]

[Cites] Eur J Biochem. 1997 Feb 15;244(1):45-52 [9063444.001]

[Cites] Science. 1985 Jan 25;227(4685):375-81 [2981433.001]

[Cites] Biochim Biophys Acta. 1991 May 6;1057(3):281-98 [1851438.001]

[Cites] Free Radic Biol Med. 2000 May 1;28(9):1387-404 [10924858.001]

[Cites] Leuk Lymphoma. 1994 Aug;14(5-6):503-7 [7812212.001]

[Cites] EMBO J. 1996 Jan 15;15(2):216-25 [8617197.001]

[Cites] J Cell Physiol. 2002 Jul;192(1):1-15 [12115731.001]

[Cites] Blood. 1994 Jul 15;84(2):440-5 [8025271.001]

[Cites] Life Sci. 1992;51(6):415-22 [1635422.001]

[Cites] Free Radic Biol Med. 1997;22(1-2):269-85 [8958153.001]

[Cites] Int Immunol. 1998 Jul;10 (7):877-89 [9701026.001]

[Cites] J Leukoc Biol. 1994 Feb;55(2):221-6 [7507967.001]

[Cites] Eur J Cell Biol. 1995 Sep;68(1):47-54 [8549589.001]

[Cites] Oncogene. 1999 Nov 22;18(49):6853-66 [10602461.001]

[Cites] J Cell Physiol. 1998 Sep;176(3):624-33 [9699515.001]

[Cites] Neurosci Lett. 1998 Apr 24;246(2):93-6 [9627188.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11233-7 [9326592.001]

[Cites] Leukemia. 1998 Oct;12(10):1545-52 [9766498.001]

[Cites] Anal Biochem. 1994 May 1;218(2):314-9 [8074286.001]

[Cites] Anticancer Res. 1995 May-Jun;15(3):687-92 [7645944.001]

[Cites] Free Radic Biol Med. 1998 Mar 15;24(5):848-54 [9586815.001]

[Cites] FASEB J. 1999 Jul;13(10):1137-43 [10385605.001]

[Cites] Antioxid Redox Signal. 2006 Nov-Dec;8(11-12):2187-92 [17034362.001]

[Cites] Biochem Biophys Res Commun. 1975 Jul 22;65(2):597-603 [167777.001]

[Cites] Free Radic Biol Med. 2000 May 1;28(9):1349-61 [10924854.001]

[Cites] Apoptosis. 2000 Nov;5(5):415-8 [11256882.001]

[Cites] Antioxid Redox Signal. 2002 Jun;4(3):405-14 [12215208.001]

[Cites] Clin Cancer Res. 1998 Dec;4(12 ):2967-76 [9865907.001]

[Cites] Exp Cell Res. 1997 Jul 10;234(1):37-46 [9223368.001]

[Cites] Eur J Biochem. 1997 May 1;245(3):730-7 [9183012.001]

[Cites] Biotechnol Bioeng. 1994 Nov 5;44(9):1140-54 [18623032.001]

[Cites] Chem Biol Interact. 1998 Apr 24;111-112:239-54 [9679558.001]

[Cites] J Biol Chem. 1998 Oct 16;273(42):27292-9 [9765254.001]

[Cites] Lymphokine Cytokine Res. 1994 Dec;13(6):399-410 [7703313.001]

[Cites] Nucleic Acids Res. 1994 Dec 11;22(24):5506-7 [7816645.001]

[Cites] Mol Carcinog. 1997 Jun;19(2):101-13 [9210957.001]

[Cites] FEBS Lett. 1997 Mar 3;404(1):27-33 [9074631.001]

[Cites] Oncogene. 1999 Nov 22;18(49):6896-909 [10602465.001]

[Cites] Free Radic Biol Med. 2000 Feb 1;28(3):463-99 [10699758.001]

[Cites] Genes Dev. 1995 Nov 15;9(22):2723-35 [7590248.001]

[Cites] Arch Biochem Biophys. 1999 May 15;365(2):211-5 [10328814.001]

[Cites] Trends Biochem Sci. 1996 Mar;21(3):83-6 [8882579.001]

[Cites] Science. 1978 Sep 8;201(4359):875-80 [210504.001]

[Cites] Free Radic Biol Med. 2009 Jan 15;46(2):244-52 [19013234.001]

[Cites] Arch Biochem Biophys. 2000 Apr 1;376(1):1-13 [10729185.001]

[Cites] Biochem Pharmacol. 1995 Sep 28;50(7):1021-9 [7575657.001]

[Cites] Cell Growth Differ. 1995 Apr;6(4):371-82 [7794805.001]

[Cites] Int J Cancer. 1996 Sep 17;67(6):842-8 [8824557.001]

[Cites] Nature. 1977 Nov 24;270(5635):347-9 [271272.001]

[Cites] Free Radic Res. 1995 Jan;22(1):23-37 [7889145.001]

[Cites] Biochem Pharmacol. 2000 Jun 15;59(12):1557-62 [10799652.001]

[Cites] Anticancer Res. 1998 Sep-Oct;18(5A):3139-52 [9858877.001]

[Cites] Biochem Pharmacol. 1994 Aug 17;48(4):675-81 [8080440.001]

[Cites] Biochim Biophys Acta. 1997 Mar 1;1355(3):353-60 [9061006.001]

[Cites] Free Radic Biol Med. 1997;22(4):623-32 [9013125.001]

[Cites] Cancer Res. 1993 Jul 1;53(13):3186-92 [8319228.001]

[Cites] Mol Immunol. 2008 Sep;45(15):3984-9 [18657320.001]

(PMID = 20224971.001).

[ISSN] 1543-706X

[Journal-full-title] In vitro cellular & developmental biology. Animal

[ISO-abbreviation] In Vitro Cell. Dev. Biol. Anim.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / NF-kappa B; EC 2.7.11.13 / Protein Kinase C; WYQ7N0BPYC / Acetylcysteine